Abstracts
Skip to Late-Breaking Abstracts »
Poster Presentation Dates
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
| # | Title | Authors | Category | Keywords |
|---|---|---|---|---|
| O4 | Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology | Courtney M. Anderson, PhD; Helly Xiao Yan Pimentel; Helen Jarnagin; Hailing Zong; Courtney Todorov; Kenneth Ganley; Fay Eng; Kevin Friedman, PhD; Molly R. Perkins; Shannon Grande, PhD; Bingqing Zhang; Christopher Bunker; Xiao-Jun Ma; James R. Rottman; Courtney M. Anderson, PhD; | Cellular Therapies | CAR T cells; Cytokine; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| O5 | The road-map to Tumor-Infiltrating Lymphocyte (TIL) therapy: Understanding genetic alterations for improved patient treatment | Caitlin Creasy, MS; Yuzhong J. Meng, PhD; Tatiana Karpinets, MS; Cara Haymaker, PhD; Marie Andrée Forget, PhD; Chip Stewart, PhD; Carlos Antonio Torres Cabala, MD; Shari A. Pilon-Thomas, PhD; Amod A. Sarnaik, MD; Levi A. Garraway, MD, PhD; Patrick Hwu, MD; Rodabe N. Amaria, MD; Rameen Beroukhim, M.D, PhD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Clinical trial; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O16 | Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216) | Alexander Stein, MD; Mascha Binder; Eray Goekkurt; Sylvie Lorenzen; Jorge Riera-Knorrenschild; Reinhard Depenbusch; Thomas Ettrich; Steffen Doerfel; Salah Al-Batran; Meinolf Karthaus; Uwe Pelzer; Donjete Simnica; Lisa Waberer; Axel Hinke; Carsten Bokemeyer; Susanna Hegewisch-Becker; Joseph Tintelnot, MD; | Clinical Trial Completed | Checkpoint blockade; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; Targeted therapy |
| O17 | A Novel Enantio-Specific Cationic Lipid R-DOTAP + HPV16 E6 & E7 Antigens Induces Potent Antigen-Specific CD8+ T Cell Responses In-Vivo in Subjects with CIN and High-Risk Human Papillomavirus Infection | Lauren V. Wood, MD; Lance H. Edwards, MD; Daron G. Ferris, MD; Nicole S. Nevadunsky, MD; Sara Isani, MD; Greg Conn, PhD; Frank Bedu-Addo, PhD; Mark Einstein, MD; | Clinical Trial Completed | Clinical study; Clinical trial; Immune adjuvant; T cell; Vaccine |
| O18 | Neoantigen vaccination targeting shared epidermal growth factor receptor (EGFR) mutations induces clinical and immunological responses in non-small cell lung cancer patients | Gregory A. Lizee, PhD; Fenge Li; Ligang Deng; Amjad Talukder; Kyle Jackson; Arjun Katailiha; Sherille Bradley; Heather Sonnemann; Qingwei Zhou; Caixia Chen; Chong Huo; Yulun Chiu; Matthew Stair; Weihong Feng; Aleksander Bagaev; Nikita Kotlov; Viktor Svekolkin; Ravshan Ataullakhanov; Natalia Miheecheva; Felix Frenkel; Yaling Wang; Minying Zhang; Jason Roszik, PhD; Ling Han; Shuo Zhou; Yan Zhang; Zhenglu Wang; Marie-Andree Forget; Chantale Bernatchez; Cassian Yee, MD; Patrick Hwu, MD; Xueming Du; Gregory A. Lizee, PhD; | Clinical Trial Completed | Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine |
| O19 | Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC) | Shailender Bhatia, MD; Candice Church, PhD; Kelly G. Paulson, MD, PhD; Robert H. Pierce, Jr., MD; Paul Nghiem, MD, PhD; John H. Lee, MD; Bridget M. Adcock, BS; Patrick Soon-Shiong, MD; Sunandana Chandra, MD; | Clinical Trial Completed | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Cytokine; NK/NK T cell; Solid tumors; T cell |
| O20 | A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma | Alexander N. Shoushtari, MD; Anthony J. Olszanski, MD, RPh; Thomas J. Hornyak, MD; Jedd D. Wolchok, MD, PhD; Sylvia Vetrhus; Karianne Risberg Handeland; Lukasz Kuryk, PhD; Magnus Jaderberg, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Immune monitoring; Tumor microenvironment; Tumor stroma |
| O21 | Safety and clinical activity of avelumab (MSB0010718C), an anti-programed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs) | Arun Rajan, MD; Haobin Chen; Chen Zhao, MD; Shannon Swift; Andrew L. Mammen; Alessandra Brofferio; Emerson Padiernos; Eva Szabo, MD; Udayan Guha; Raffit Hassan, MD; Seth M. Steinberg; Yo-Ting Tsai; Renee N. Donahue, PhD; Jeffrey Schlom; James L. Gulley, MD, PhD, FACP; | Clinical Trial Completed | Autoimmunity; Checkpoint blockade; Clinical trial; Immune monitoring; Immune toxicity; Solid tumors |
| O22 | Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma | Daniela Bota; David E. Piccioni, MD, PhD; Renato V. LaRocca, MD; Christopher M. Duma, MD; Robert D. Aiken, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD, FACP; | Clinical Trial In Progress | Clinical trial; Dendritic cell; Immune monitoring; Neoantigens; Stem cell/cancer-initiating cell; Vaccine |
| O23 | Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI) | Pavlos Msaouel, MD, PhD; Arlene Siefker-Radtke, MD; Randy F. Sweis, MD; Amir Mortazavi; Nicholas J. Vogelzang, MD; Ulka N. Vaishampayan, MD; Thomas Bradley, MD; Manojkumar Bupathi; Luke T. Nordquist, MD, FACP; David R. Shaffer; Joel Picus; Jeffrey Yorio, MD; Shifeng Mao; Gurjyot K. Doshi; Daniel L. Spitz; Sunil Gandhi; Daniel Chong; Arash Rezazadeh Kalebasty; James Christensen; Peter Olson; Demiana Faltaos, PharmD, PhD; Ronald L. Shazer; Maria Winter; Delia Alvarez; Hirak Del-Torossian; Jonathan E. Rosenberg, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| O24 | Phase II Trial of Concurrent Nivolumab and Radiation Therapy in Chemotherapy Ineligible Muscle Invasive Bladder Cancer [NUTRA trial NCT03421652] | Ulka N. Vaishampayan, MD; Saby George, MD, FACP; Lance Heilbrun; Jordan Maier, MD; Brenda Dickow; Michael Kuettel, MD; Arthur Frazier, MD; Stacey M. Suisham, RN BSN OCN CcRP; Prahlad Parajuli, PhD; Nitin Vaishampayan, MD; Ulka N. Vaishampayan, MD | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Tumor microenvironment |
| O25 | Dominant Negative PD1 Armored CART Cells Induce Remission in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients | Cheng fei Pu; Lei Xiao, PhD | Clinical Trial In Progress | B cell; CAR T cells; Checkpoint blockade; Clinical study; Clinical trial; Leukemia/Lymphoma; T cell lineages; Targeted therapy; Tumor microenvironment |
| O26 | A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis | Matthew G. Krebs, MD PhD; Paal F. Brunsvig, MD PhD; Åslaug Helland; Nuria Vinolas Segarra; Santiago Ponce Aix, MD; Enric Carcereny Costa, MD; Manuel Dómine Gomez, MD, PhD; Jose Manuel Trigo Perez; Edurne Arriola; Rosario Garcia Campelo; James Spicer, MD, PhD; Jonathan Thompson, MD MS; Ana Laura Ortega Granados; Robert Holt, PhD; James Lorens, PhD; Muhammad Shoaib, MD; Abdul Siddiqui; Emmett Schmidt, MD PhD; Michael J. Chisamore, PhD; Enriqueta Felip, MD PhD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| O27 | Clinical Response to Tumor Infiltrating Lymphocytes (TIL) in Stage 4 Non-small Cell Lung Cancer (NSCLC) Correlates with Neoantigen-Specificity: a Phase I Trial | Chao Wang, PhD; Jamie Teer; Jiqiang Yao, PhD; Anadon Galindo Carmen M; David Noyes; Eric Toloza; John E. Mullinax, MD; Ana Landin; Jhanelle Gray; Tawee Tanvetyanon; Andreas Saltos; Linda L. Kelley, PhD; Bin Fang, PhD; John Koomen, PhD; Amod A. Sarnaik, MD; Sungjune Kim, MD PhD; Shari A. Pilon-Thomas, PhD; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD. PhD; Eric Haura, MD; Ben C. Creelan, MD, MS; | Clinical Trial In Progress | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| O28 | First-in-Class Small Molecule CA-170 Targeting VISTA: A Report on Efficacy Outcomes from a Cohort of 12 Malignant Pleural Mesothelioma (MPM) Patients in Study CA-170-101 | Marjorie G. Zauderer, MD, MS, FACP; Joshua Brody, MD; Thomas U. Marron, MD PhD; Simon Pacey; Robert Martell; Hongwei Wang; James Spicer, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| O29 | Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors | Corey C. Foster, MD, MS; Jason J. Luke, MD, FACP; Robyn Hseu, CCRP, MLIS; Linda Janisch; Gini Fleming, MD; Steven J. Chmura, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| O30 | A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors | Ben Markman, MBBS FRACP; Ben Tran; Hui Gan, MBBS PhD; Amy Prawira, MD; Jermaine Coward; Xiaoping Jin; Baiyong Li; Max Wang; Yu Xia; Jayesh Desai, MBBS FRACP; Jayesh Desai, MBBS FRACP; Michael Millward; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical trial; Solid tumors |
| O31 | Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types | Jacob Thomas, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, M.S., M.A, M.B.A.; Ian B. Walters, MD; Giles F. Whalen, MD; Diana Hanna, MD; Vinay Duddalwar, MD; Phillip Cheng, MD; Kevin King, MD; Lilian L. Siu, MD; Anthony El-Khoueiry, MD; | Clinical Trial In Progress | Chemotherapy; Clinical trial; Dendritic cell; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| O32 | Single agent anti-tumor activity in PD-1 refractory NSCLC: phase 1 data from the first-in-human trial of NC318, a Siglec-15-targeted antibody | Anthony Tolcher, MD; Omid Hamid, MD; Jeffrey S. Weber, MD, PhD; Patricia LoRusso, DO; Kathryn Shantz; Kevin N. Heller, MD; Kevin Heller, MD; Martin Gutierrez, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Tumor antigens; Tumor evasion; Tumor microenvironment |
| O33 | Immune enrichment and functional T-cell receptor (TCR) frequencies predict response to immune checkpoint blockade (ICB) in selected fusion-associated sarcomas | Akash Mitra, BS; Neeta Somaiah, MD, MBBS; Anthony P. Conley, MD; Behrang Amini; Heather Lin; Beatriz Sanchez Espiridion; Celia Garcia-Prieto; Grace Mathew; Latasha Little, BS; Xingshi Song; Curtis Gumbs, BS; Cara Haymaker, PhD; Jianhua Zhang; Zachary A. Cooper, PhD; Michael D. Oberst, PhD; Chantale Bernatchez; Vinod Ravi; Dejka Araujo, MD; Maria Zarzour; John Livingston; Christina Roland, MD, MS, FACS; Najat Daw, MD; Jaime Rodriguez-Canales, MD; Alexander J. Lazar, MD, PhD; Wei-Lien Wang; Ignacio Wistuba, MD; Jean-Charles Soria, MD, PhD; Robert Benjamin; Shreyaskumar Patel; Patrick Hwu, MD; Phillip Andrew Futreal, PhD; | Clinical Trial In Progress | Bioinformatics; Checkpoint blockade; Clinical trial; Gene expression; Immune monitoring; Immunoscore; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O34 | Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High Risk Resectable Melanoma (MEL): Preliminary Results. | Diwakar Davar, MD; Arivarasan Karunamurthy; Douglas Hartman; Mignane Ka; Carmine Menna; Julie Burkette; Joe-Marc JM. Chauvin, PhD; Lucas Rubuffet; Shuowen Zhang; Quanquan Ding; Amy Rose; Kellie Sellitto; Yana G. Najjar, MD; Matthew Holtzman; James Pingpank; Shaum Sridharan; Umamaheshwar Duvvuri; Hagop Youssoufian; Barry Labinger; Arthur Krieg; John M. Kirkwood, MD; Hassane M. Zarour, MD; | Clinical Trial In Progress | Clinical trial; T cell; TLR |
| O35 | Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study | Adi Diab, MD; Igor Puzanov, MD, MSCI, FACP; Michele Maio, MD, PhD; Brendan D. Curti, MD; Mehmet A. Bilen; Karl D. Lewis, MD; Scott S. Tykodi, MD, PhD; Gregory A. Daniels, MD, PhD; Alexander I. Spira, MD, PhD, FACP; Chantale Bernatchez; Salah Eddine Bentebibel; Michael K. Wong, MD PhD FRCPC; James Larkin, MD; Ewa Kalinka, PhD, MD; Sunny Xie; Sue Currie; Ute Hoch, PhD; Wei Lin; Mary A. Tagliaferri, MD; Stina Singel; Michael E. Hurwitz, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Cytokine; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O36 | A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors | Thomas Eigentler, Dr.; Juergen Krauss; Jutta Schreiber, Dr; Carsten Weishaupt; Patrick Terheyden; Lucie Heinzerling; Peter Mohr; Benjamin Weide, MD; Sebastian Ochsenreither; Juergen C. Becker, MD, PhD; Franz-Georg Bauernfeind, Dr; Peter Brossart; Fatma Funkner; Regina Heidenreich; Sarah-Katharina Kays; Anke Muth; Tobias Seibel, II; Birgit Scheel; Oliver Schoenborn-Kellenberger; Claudia Stosnach; Angelika Daehling; Tanja Strack; Roman P. Korolkiewicz; Ulrike Gnad-Vogt, MD | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Inflammation; TLR; Tumor microenvironment; Vaccine |
| O40 | Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers | Jason J. Luke, MD, FACP; Jaime Merchan; Lauren Harshman, MD; Thomas U. Marron, MD PhD; John D. Powderly, II, MD, CPI; Minal Barve; Patricia LoRusso, DO; Melissa Johnson; Andrew Hotson, PhD; Rachel Gittelman, PhD; Brian Munneke; Joseph J. Buggy; Stephen Willingham, PhD; Emily C. Piccione, PhD; Mehrdad Mobasher; Richard A. Miller, MD; Richard A. Miller; | Combination Immunotherapies | Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Clinical trial; Targeted therapy |
| O51 | Sirt2 inhibition enhances anti-tumor immunity by promoting T cell metabolism | Imene Hamaidi, PhD; Lin Zhang, MD. Ph.D; Nayoung Kim, Ph.D; Min-Hsuan Wang; Cristina Iclozan, PhD; Bin Fang, PhD; Min Liu, PhD; John Koomen, PhD; Anders E. Berglund, PhD; Sean J. Yoder; Jiqiang Yao, PhD; Ben C. Creelan, MD, MS; Scott J. Antonia, MD. PhD; Sungjune Kim, MD PhD; | Immune Cell Biology | Checkpoint blockade; Clinical trial; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O67 | Variation in the commensal urinary microbiome is associated with response to Bacillus Calmette-Guérin (BCG) immunotherapy in early stage urothelial bladder cancer. | Randy F. Sweis, MD; Randy F. Sweis, MD; Ciro Andolfi; Jeffrey Bloodworth; Shay Golan, MD; Nimrod Barashi; Elle Hill; Ryan Werntz; Thomas F. Gajewski, MD, PhD; Gary D. Steinberg, MD; | Microbiome and other environmental factors | Biomarkers; Chemokine; Clinical study; Cytokine; Immune contexture; Microbiome; Solid tumors; Tumor microenvironment |
| O68 | Characteristics of the microbiome form and function of complete responders to Anti-PD1 and healthy individuals implicate donor selection for clinical trial design | Md Abdul Wadud Khan, PhD; Jennifer A. Wargo, MD, MMSc; Beth Helmink, MD PhD; Elizabeth Burton; Christine N. Spencer, PhD; Jennifer L. McQuade, MD; Miles Andrews, MD, PhD; Alexandria Cogdill; Lauren E. Haydu, MS, BChe, MIPH; Reetakshi Arora; Angela L. Harris; Vanessa B. Jensen, DVM; Adrienne F. Duran, B.A.S.; Linsey Martin; Elizabeth Sirmans; Sapna Patel, MD; Tim Heffernan; Robert Jenq, MD; Michael K. Wong, MD PhD FRCPC; Jeffrey E. Gershenwald, MD; Tawbi Hussein; Isabella C. Glitza, MD, PhD; Patrick Hwu, MD; Michael Davies, MD, PhD; David Cook; Jennifer Wortman; Theresa LaVallee, PhD; Adi Diab, MD; Vancheswaran Gopalakrishnan; Md Abdul Wadud Khan, PhD; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Microbiome |
| O71 | AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells | Sterling C. Eckard, PhD; Leah N. Gehrs; Victoria Smith; Jeanmarie Guenot; John F. DiPersio; Sheng Wei, MD; Michael P. Rettig; | Novel Single-Agent Immunotherapies | Clinical trial; Immune suppression; Leukemia/Lymphoma; Myeloid cells; MDSC; Solid tumors; T cell; Targeted therapy |
| O80 | Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors | Bogdan Luca; Ash Alizadeh; Max Diehn; Aaron Newman; Andrew Gentles, PhD; Chloé Steen; Andrew Gentles, PhD; | Tumor and Stromal Cell Biology | Bioinformatics; Biomarkers; Gene expression; Immune contexture; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| O81 | IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1–selected NSCLC | Roy Herbst, MD, PhD, Filippo De Marinis, Giuseppe Giaccone, Niels Reinmuth, Alain Vergnenegre, Carlos Barrios, Masahiro Morise, Enriqueta Font, Zoran Andric, Sarayut Geater0, Mustafa Ozguroglu, Simonetta Mocci, Mark McCleland, Ida Enquist, Kim Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Jacek Jassem, David Spigel, MD | Clinical Trial Completed | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Solid tumors |
| O82 | A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies | Sarina Piha-Paul, MD, Johanna Bendell, MD, Anthony Tolcher, Sara Hurvitz, MD, Amita Patnaik, MD FRCP(C), Rachna Shroff, Paula Pohlmann, Markus Zettl, Noah Hahn, MD, Anuradha Krishnamurthy, MD0, Manuela Duerr, Jian Mei, Kayti Aviano, Rushdia Yusuf, MD, MPH, Louis Matis, MD, Shane Olwill, PhD, Ingmar Bruns* , Geoffrey Ku | Clinical Trial In Progress | Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O83 | Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | Ronnie Shapira-Frommer, Marloes G. J. van Dongen, Konstantin Dobrenkov, Elliot Chartash, Fang Liu, PhD, Claire Li, Richard Wnek, Manish Patel, MD | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy |
| O85 | Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab | Mohammed Milhem, MBBS, Yousef Zakharia, MD, Diwakar Davar, MD, Elizabeth Buchbinder, MD, Theresa Medina, MD, Adil Daud, MD, Antoni Ribas, MD, PhD, Jiaxin Niu, Geoffrey Gibney, MD, Kim Margolin, MD, Anthony Olszanski, MD, RPh0, Interjit Mehmi, Takami Sato, MD, Montaser Shaheen, Aaron Morris, David Mauro, Katie Campbell, Riyue Bao, George Weiner, MD, Jason Luke, MD, FACP, Arthur Krieg, John Kirkwood, MD | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical trial; Cytokine; Dendritic cell; Inflammation; Regulatory T cell (Treg cell); Solid tumors; TLR; Tumor microenvironment |
| P5 | Laminar Wash™ AUTO system: a reliable walk-away sample preparation solution for better TIL recovery without centrifugation | Ira Kim; Melvin Lye; Roberta Zappasodi, PhD; Isabell Schulze; Christoph CE. Eberle, PhD; Chyan Ying Ke; Kong Leong Cheng; Ih Chin Kon; Royce Pek; Taha Merghoub, PhD; Namyong Kim, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Clinical trial; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P9 | Immune checkpoint biomarkers in hepatocellular carcinoma (HCC): Assessment of PD-L1 and tumour mutation burden in tumour samples from clinical patients | Hisani Horne, PhD, MPH; Young S. Lee; Todd Creasy; Rebecca Fish; Jonathan Cairns; Paul Scorer; Janine Feng; Marietta Scott, PhD; Mark Gustavson; Aleksandra Dudek-Madej; Craig Barker; Nicholas Holoweckyi; Rebecca Halpin; Peiyi Wang; Quinea Lassiter; Xiaoling Xia; Mohammed Abdelwahab; Weimin Li; Alejandra Negro; Jill Walker; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immunoscore |
| P11 | Early detection of breast cancer (BCa) through MDSC and lymphocyte immunophenotyping: from manual gating to pattern recognition neural networks | George A. Dominguez, PhD; John Roop; Alexander Aa. Polo, BS; Anthony Campisi, BS; Dmitry I. Gabrilovich, MD/PhD; Amit Kumar, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical study; Immune monitoring; Myeloid cells; MDSC |
| P13 | Immunomodulatory effects of Interleukin 2 in the circulation of melanoma patients and the added impact of VEGF inhibition with Ziv-aflibercept | Arjun Khunger, MD; Ghanashyam Sarikonda; Paul Frankel, PhD; Jenn Tsau, PhD; Zeni Alfonso, PhD; Jane Gao, MS; Anil Pahuja, BSc; Christine A. Vaupel, PhD; Naveen Dakappagari; Shabnam Tangri, PhD; Ahmad A. Tarhini, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Immune suppression; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell |
| P14 | Validation of Dendritic Cell and Natural Killer Cell Signatures for Clinical Biomarker Development | Bolan Linghu, PHD; Pei Zhang, PhD; Marylens Hernandez; Mingchao Xie, PhD; Christine Barbon; Srimathi Srinivasan; Deanna Russell, M.S.; Anna Coenen-Stass; Deanna A. Mele, PhD; Patricia McCoon, PhD; Jonathan Dry; Ben Sidders; Kris Sachsenmeier, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Dendritic cell; Gene expression; Immune monitoring; NK/NK T cell |
| P16 | Circulating immunological biomarkers for predicting response to neoadjuvant chemotherapy in TNBC patients | Charlotte K. Milton, PhD; Thanussuyah Alaguthurai; Atousa khiabany, Mres; Sheeba Irshad, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Chemokine; Chemotherapy; Clinical study; Cytokine; Immune contexture; Immune monitoring; Solid tumors |
| P21 | Activation Profiling of tumor infiltrating CD8+ T cells reveals CTLA-4 mean fluorescence intensity correlates with response in treatment naïve melanoma. | Lauren S. Levine, MD; Katy Tsai, MD; James C. Lee, MD; Clinton Wu, BS; Kelly Mahuron, MD; Alain Algazi, MD; Michael G. Rosenblum, MD PhD; Adil Daud, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P59 | Highly Consistent automated multiplex immunofluorescence for immunoprofiling of solid tumors in clinical trials: assay validation study using multispectral imaging and digital analysis. | Jaime Rodriguez-Canales, MD; Michael J. Surace, PhD; Lorenz Rognoni, PhD; Farzad Sekhavati; Andrew Fisher, PhD; Andreas Spitzmueller; Sara Batelli, PhD; Karma Dacosta; Vinay Pawar; Clifford Hoyt; Edwin R. Parra, MD., PhD; Jaime Rodriguez-Canales, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Solid tumors |
| P63 | Clinical Assay Development and Validation of Multiplex Immunofluorescent (mIHC) Marker Panel for Evaluation of Tumor Infiltration Myeloid Cells in FFPE Tissue Sections | Lan Yi, Ph.D; Jonathan Juco, MD; Ashhad Mahmood, MD; Omar F. Laterza; Charo Garrido; Lan Yi, Ph.D; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Granulocyte; Immune monitoring; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor microenvironment |
| P65 | Mutation-Targeted T Cell Responses in Blood from Patients with Solid Tumors Prior to Treatment and which Evolve with Clinical Benefit from Anti-PD-1 Therapies | Benjamin T. Yuen, PhD; Fangfang Yin, PhD; Duo An, PhD; Boi Quach; Linlin Guo, PhD; Joanne BL. Tan, PhD; Songming Peng, PhD; Zheng Pan, PhD; Olivier Dalmas, PhD; Robert Bao, PhD; Kyle Jacoby, PhD; Barbara Sennino, PhD; Stefanie J. Mandl, PhD; Matt Walters, PhD; Juan C. Jaen, PhD; Alex Franzusoff, PhD; Benjamin T. Yuen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P66 | A novel mass cytometry-based immunomonitoring platform for characterizing the peptide vaccine-induced immune response of HLA-A*0201+ patients with K27M+ diffuse midline gliomas | Jared Taitt, BA; Payal Watchmaker, PhD; Takahide Nejo, MD, PhD; Neil Almeida; Kaori Okada; Sabine Mueller, MD PhD; Hideho Okada, MD, PhD; Jared Taitt, BA; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical trial; Immune monitoring; Immune suppression; MDSC; Neoantigens; Pediatric tumors; T cell; Vaccine |
| P80 | HER2 is associated with prolonged survival in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade | Carrie B. Brachmann, PhD; Emon Elboudwarej; Manish Shah, MD; David Cunningham; Jean-Philippe Metges; Eric Van Cutsem, MD, PhD; Zev Wainberg, MD; Jingzhu Zhou; Dung Thai; Pankaj Bhargava; Daniel V. Catenacci, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment |
| P81 | Association of tumor mutational burden with clinical, genomic, and treatment characteristics in advanced non-small cell lung cancer | Connor Willis, PharmD; Hillevi Bauer, PharmD; Trang H. Au, PharmD; Sudhir Unni, PhD, MBA; Wallace Akerley, MD; Ashley Sekhon, MD; Firas Badin, MD; John L. Villano, MD, PhD; Matthew B. Schabath, PhD; Bing Xia, MD; Beth Gustafson, PharmD; Komal Gupte-Singh, PhD; Beata Korytowsky; John-michael Thomas, PharmD; Gabriel Krigsfield, PhD; Solomon J. Lubinga, PhD; diana brixner, PhD; David Stenehjem, PharmD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors |
| P95 | Single-cell RNA-sequencing from clinically relevant core needle biopsies for evaluation of tumor-immune cell interactions in the tumor microenvironment | Namit Kumar, PhD; Mohan Bolisetty; Peter Szabo, PhD; Xuan Li; Becky Penhallow; Ryan Golhar; Alice M. Walsh; Saumya Pant; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P104 | Impact of chemotherapy (chemo) on peripheral T-cell diversity and implications for subsequent immunotherapy response in breast cancer | Joanna Pucilowska, PhD; Paul Fields, PhD; Valerie K. Conrad, BS; David B. Page, MD; Alison K. Conlin, MD; Joanna Pucilowska, PhD; Catherine Sanders, PhD; Raina A. Tamakawa, MS; Brie M. Chun, MD; Isaac K. Kim, MD; Mark Schmidt; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Clinical study; Immune monitoring; T cell |
| P106 | Tumor Mutational Burden profile (TMB) of Oncogenic Driver Mutations in Non Small Cell Lung Cancer | Nitika Sharma; Paul R. Walker, MD; Nitika Sharma; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; Targeted therapy |
| P109 | Predictive performance of a CD8-derived signature by gene expression profiling in patients with urothelial carcinoma from CheckMate 275 | Peter Szabo, PhD; Padmanee Sharma, MD, PhD; George Lee, PhD; Scott Ely; Vipul Baxi, MS; Keyur Desai, PhD; Lisu Wang; Robin H. Edwards, PhD; Saumya Pant; Abdel Saci; Neeraj Adya; Matthew D. Galsky, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Inflammation; T cell |
| P110 | Tumor CD8+ T-cell infiltration assessed by gene expression profiling alone or by immunohistochemistry plus epithelial-mesenchymal transition gene expression in urothelial carcinoma in CheckMate 275 | Peter Szabo, PhD; Abdel Saci; Padmanee Sharma, MD, PhD; George Lee, PhD; Scott Ely; Vipul Baxi, MS; Keyur Desai, PhD; Lisu Wang; Scott D. Chasalow; Michael Montalto; Robin H. Edwards, PhD; Saumya Pant; Neeraj Adya; Bruce Fischer, MD; Matthew D. Galsky, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Inflammation; T cell |
| P111 | Clinical and Immunologic Implications of a Microsatellite Instability Score in Lung Cancer | Pedro Viveiros, MD; Misuk Lee; Bhoomika Sukhadia, MD; Kyunghoon Rhee; Victor Wang; Jeffrey Chuang; Young Kwang Chae, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immunoscore; Neoantigens; Solid tumors |
| P117 | Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project | Florence Monville, PhD; Frederic Vely; Joseph Ciccolini; Florence Sabatier; Stephane Garcia; Vanina Leca; Marion Fabre; Christelle Piperoglou; Pernelle Outters; Laurent Arnaud; Laurent Vanhille, PhD; Caroline Lauge, BA; Anna Martirosyan, Dr; Aurelie Collignon; Marie Roumieux; Julien Mazieres; Maurice Perol; Françoise Dignat-George; Eric Vivier; Fabrice Barlesi, MD, PhD; Jacques Fieschi, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune contexture; Immune monitoring; Immunoscore; MDSC; Tumor infiltrating lymphocytes (TILs) |
| P128 | Pooled analysis of Programmed Death Factor Ligand 1 (PD-L1) expression as a predictive biomarker using individual data on 7,918 randomized study patients | Andrea Arfe; Geoffrey Fell; Brian Alexander, MD MPH; Mark Awad, MD PhD; Scott J. Rodig, MD, PhD; Lorenzo Trippa; Jonathan Schoenfeld, MD, MPH; Jonathan Schoenfeld, MD, MPH; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Solid tumors |
| P130 | Melanoma patients harbor pre-existing IgG autoantibodies targeting neuronal proteins that associate with differential clinical outcomes following checkpoint blockade | Tyler Hulett, PhD; Michael Gowen, MD; Keith Giles; Danny Simpson; Jeremy Tchack; Una Moran; Zarmeena Dawood; Anna C. Pavlick, MD, MBA; Shaohui Hu; Hua Zhong; Michelle Krogsgaard; Tomas Kirchhoff, PhD; Iman Osman; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Autoimmunity; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Proteomics; Tumor antigens |
| P131 | Single cellular interrogation of tumor microenvironment enables diagnosis and prognostication of malignancies | Wei Jian Tan; Jian Hang Lam; Mona Meng Wang; Paola Ricciardi-Castagnoli; Anita Sook Yee Chan; Tony Kiat Hon Lim; Joe Poh Sheng Yeong; Tong Seng Lim, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Biomarkers; Clinical study; Immune monitoring; Leukemia/Lymphoma; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P133 | High tumor expression of DKK1 is associated with improved clinical benefit and longer progression free survival across multiple solid tumors when treated with a targeted anti-DKK1 antibody (DKN-01) | Michael Kagey, PhD; Girish Naik, MD; Michael Haas, PhD; Heidi Heath; Franziska Schurpf-Huber; Walter Newman, PhD; Cynthia Sirard, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; NK/NK T cell; Solid tumors |
| P141 | One-year progression-free survival in lung cancer patients treated with immune checkpoint inhibitors is significantly associated with a novel immunomodulatory signature but not PD-L1 staining | Harsha A. Ranganath, MD; Amit Jain; Justin R. Smith; Julie Ryder; Amina Chaudry; Emily Miller; Felicia Hare; Poojitha Valasareddy; Rob Seitz; David R. Hout; Brock L. Schweitzer; Tyler J. Nielsen; Janice Mullins; Gregory Vidal; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Immune monitoring; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P147 | Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients. | Erik Marcelo Alcantar Orozco; Eytan Breman, MSc; Marie-Sophie Dheur, PhD; Fabian Borghese, PhD; Emilie Cerf, PhD; Nathalie Braun; Caroline Lonez, PhD; Anne Flament; Frederic Lehmann, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell |
| P150 | 1st-in-human CAR T clinical trial for metastatic breast cancers | Cynthia C. Bamdad, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Benoit J. Smagghe, PhD; Scott T. Moe, PhD; Tyler E. Swanson; Thomas G. Jeon; Danica M. Page; Ketan M. Mathavan, PhD; Trevor J. Grant, PhD; Rachel M. Herrup; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P173 | Case reports: Correlates of response following adoptive transfer of ADP-A2M4, affinity-enhanced T-cells targeting MAGE-A4, in synovial sarcoma | Svetlana Fayngerts, PhD; Zohar Wolchinsky; Shravani Shitole; Joana Senra; Rebecca Dryer-Minnerly, PhD; Ruoxi Wang; Jean-Marc Navenot, PhD; Olga Ochkur; Gareth Betts, PhD; Natalie Bath, MSc; Erin Van Winkle; Tom Holdich; Malini Iyengar, PhD; Rafael Amado, MD; Marcus O. Butler, MD; David S. Hong, MD; Alex J. Tipping, PhD; Samik Basu, MD; Indu Ramachandran, PhD | Cellular Therapies | Adoptive immunotherapy; Clinical study; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P176 | Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for metastatic uveal melanoma: feasibility of treatment using a product generated from the primary tumor | Marie-Andree Forget, PhD; Cara Haymaker, PhD; Orenthial J. Fulbright, BS; Shawne Thorsen, BS; Esteban Flores, BS; Arely Wahl, MSc; Rene J. Tavera, BS; Benjamin Tintera, BS; Timothy L. Woody; Michelle Williams; Yun Shin Chun; Patrick Hwu, MD; Dan S. Gombos; Sapna Patel, MD; Rodabe N. Amaria, MD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P180 | SENTI-101, an allogeneic cell product, induces potent and durable anti-tumor immunity in pre-clinical models of peritoneal carcinomatosis | Alba Gonzalez Junca, PhD; Gary Lee, PhD; Alba Gonzalez Junca, PhD; Archana Nagaraja, PhD; Alyssa Mullenix; Russell M. Gordley, PhD; Daniel O. Frimannson, PhD; Anissa Benabbas; Chen-Ting Lee, PhD; Tiffany A. Truong; Mengxi Tian; Allison Bi. Quach; Rishi Savur; Rowena Martinez; Alyssa Perry-McNamara; Don-Hong Wang, PhD; Ori Maller, PhD; Dharini Iyer, PhD; Ashita Magal; Christina J. Huynh; Carmina C. Blanco; Jack T. Lin, PhD; Brian S. Garrison, PhD; Philip Lee, PhD; Sravani Mangalampalli; Timothy K. Lu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; Tumor microenvironment |
| P190 | Single-day CAR manufacturing platform using mRNA and Flow Electroporation Technology | Michael Kuo; Robert Keefe, PhD; Linhong Li, PhD; Angelia Viley; Mary Loveras; Brian Mulhern; Melanie Hartsough; Robert Keefe, PhD; Claudio A. Dansky Ullmann, MD; Dhana Chinnasamy; | Cellular Therapies | CAR T cells; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P210 | Deep phenotypic and functional analysis of transduced anti-CD19 CAR T cells and untransduced T cells in patients treated with axi-cel by single cell mass cytometry | Yohei Arihara, MD, PhD; Caron Jacobson, MD; Philippe Armand, MD; John M. Rossi, MS; Nathalie Scholler, MD, PhD; Stuart Sievers, PhD; Edmund Chang, PhD; Mauro Avanzi, MD, PhD; Adrian Bot, MD, PhD; Jerome Ritz, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Clinical study; Immune monitoring; Leukemia/Lymphoma |
| P212 | Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy | Donastas Sakellariou-Thompson, BS; Marie-Andree Forget, PhD; Emily Hinchcliff, MD; Joseph Celestino; Patrick Hwu, MD; Amir A. Jazaeri, MD; Cara Haymaker, PhD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P224 | Case studies of sarcoma and MRCLS following treatment with NY-ESO-1 TCR T Cells (GSK3377794): correlates of predictable response characteristics | Brian Van Tine, MD, PhD; Sandra P. D'Angelo, MD; Alexandra Gyurdieva; Laura Johnson; David C. Turner; Jenna Tress; M. Phillip DeYoung; Yuehui Wu; Aisha N. Hasan, MBBS MD; Dejka Araujo, MD; | Cellular Therapies | Adoptive immunotherapy; Clinical study; Cytokine; T cell |
| P230 | Activating Antigen Carriers for Cancer Therapy: Preclinical Immune Responses Drive Tumor Regression | Defne Yarar, PhD; Amritha Ramakrishnan; Katarina Blagovic, PhD; Katherine Seidl; Howard Bernstein, MD, PhD; Armon Sharei; | Cellular Therapies | Adoptive immunotherapy; Immune adjuvant; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P239 | Immune checkpoint inhibitor-associated arthritis: a systematic literature review of case series and case reports | Michael D. Tiongson, BA; Nilasha Ghosh, MD; Carolyn Stewart, BA; Karmela K. Chan, MD; Bridget J. Gatto, MLIS; Anne R. Bass, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Clinical study; Immune toxicity; Inflammation |
| P241 | Single-cell deconvolution identifies T-cell correlates of response to PD-1 blockade treatment in AML | Xingyue An, BS; Jay R Adolacion; Mansour Alfayez; Jairo Matthews; Wilmer Flores; Steven M. Kornblau, MD; Arash Saeedi; Naval Daver, MD; Sreyashi Basu; Navin Varadarajan, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Leukemia/Lymphoma; T cell |
| P252 | A Retrospective Study to Evaluate Real-World Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Ipilimumab and Nivolumab. | Landon C. Brown, MD; Emily N. Kinsey, MD; Chester Kao, MD; Patrick Healy; Andrew J. Armstrong, MD; Megan A. McNamara, MD; Sundhar Ramalingam, MD; Michael R. Harrision, MD; Daniel J. George, MD; Tian Zhang, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| P253 | Distinct clinical and immunological responses to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences | Myrna G. Garcia, BS; Alvaro Padron; Yilun Deng, MD, PhD; Harshita B. Gupta, PhD; Aravind Kancharla; Tyler Curiel, MD; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Costimulation; Cytokine; Dendritic cell; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P255 | Preclinical characterization and efficacy of MG1124, a Novel Immune Checkpoint Blockade targeting CEACAM1 for cancer therapy | Jae-Chul Lee, Master degree; Jae-Chul Lee, Master degree; Minkyu Hur; Hye-Young Park; Mi-Young Oh; Hye-mi Nam; Hye In Yum; HyungSuk Choi; Jaehwan Kim; Byoung Chul Cho, MD.phD; Yangmi Lim; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; NK/NK T cell; T cell; Targeted therapy |
| P260 | Characterization of AB154, a Humanized, Non-depleting α-TIGIT Antibody Undergoing Clinical Evaluation in Subjects with Advanced Solid Tumors | Joanne BL. Tan, PhD; Alejandra Lopez, BSc; Joanne BL. Tan, PhD; Amy Anderson, PhD; Akshata Udyavar, Ph.D; Nell Narasappa, MSC.; Susan J. Lee, PhD; Daniel DiRenzo, PhD; Kristen Zhang, BS; Hema Singh; Sharon Zhao; Kimberline Gerrick; Adam Park; Lisa Seitz, MA; Nigel PC. Walker, PhD; Matthew J. Walters, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune contexture; Immune monitoring; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P265 | Immune checkpoint inhibitors induce response in a dose-dependent manner while their immune related adverse events are dose-independent, a meta-analysis | Osama E. Rahma, MD; Joshua E. Reuss, MD; Anita Giobbie-Hurder, MS; Ghazaleh Razavi, MD; Pooja Mehra, MD; Seema Gupta; Rawad Elias, MD; Samir Khleif, MD; Osama E. Rahma, MD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors |
| P267 | Phenotyping of TIGIT pathway members may be used for cancer selection in the clinical application of anti-TIGIT antibody EOS884448 | Noemie Wald, PhD; Julia Cuende, PhD; Marjorie Mercier; Florence Nyawouame, MSc; Margreet Brouwer, MSc; Erica Houthuys, PhD; Gregory Driessens, PhD; Veronique Bodo, PhD; Catherine Hoofd; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Coinhibition; Costimulation; Immune contexture; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P270 | Expression and clinical significance of the CD47/SIRPα pathway as a candidate immunotherapy target in non-small cell lung cancer (NSCLC) | Shruti Desai, PhD; Franz Villarroel-Espindola; Patricia Gaule, PhD; Adam Ducler; Marisa Peluso, MS; Benjamin Lee, MD PhD; Pamela Holland, PhD; Kurt A. Schalper, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P272 | SRF231, a fully human high-affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the Fc receptor (FcR), CD32a | Marisa Peluso, MS; Kshama Doshi, PhD; Caroline M. Armet, BS; Li Zhang; Rachel W. O'Connor, BS; Matthew P. Rausch, PhD; Jonathan A. Hill, PhD; Benjamin Lee, MD PhD; Pamela Holland, PhD; Vito J. Palombella, PhD; Alison M. Paterson, PhD; | Checkpoint Blockade Therapy | Antibody; Monocyte/Macrophage; Myeloid cells; Targeted therapy |
| P276 | Efficacy of PD-1/PDL-1 Immune Checkpoint Inhibitors in Elderly Patients with Non-Small-Cell Lung Cancer; A Subgroup Meta-analysis of Randomized Controlled Trials | Faisal S. Ali; Maryam R. Hussain; Arafat Farooqui; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Clinical trial; Immune monitoring; Tumor microenvironment |
| P277 | Utility of PD-L1 Expression in Non-Small-Cell Lung Cancer Patients Treated with PD-1/PDL-1 Immune Checkpoint Inhibitors; A Subgroup Meta-analysis of Randomized Controlled Trials | Faisal S. Ali; Maryam R. Hussain; Arafat Farooqui; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors |
| P284 | Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice | Tiina E. Kähkönen; Mari I. Suominen; Jenni HE. Mäki-Jouppila; Emrah Yatkin; Philip Dube; Azusa Tanaka; Jussi M. Halleen; Jenni Bernoulli, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P293 | Tumor mutational burden (TMB) and genomic predictors of clinical outcomes to PD-1/PD-L1 checkpoint blockade in high-grade gliomas | Bryan Iorgulescu, MD; Mehdi Touat; Yvonne Li; Liam Spurr; Gareth Grant; William Pisano; Mary Jane Lim-Fat; Eudocia Lee; Lakshmi Nayak; E Chiocca; Raymond Huang; Andrew Cherniack; Patrick Wen; Ahmed Idbaih; Franck Bielle; David A. Reardon, MD; Keith Ligon; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study |
| P294 | Long survival associated with receipt of anti-CTLA-4 in patients with metastatic melanoma from acral lentiginous, mucosal and uveal primary tumors | Nicholas D. Klemen, MD; Melinda Wang, BS; Kelly Olino, MD; James Clune, MD; Stephan Ariyan, MD; Charles Cha, MD; Sarah A. Weiss, MD; Harriet Kluger, MD; Mario Sznol, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Neoantigens; Surgery; Tumor antigens; Tumor evasion |
| P304 | DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer | Biagio Ricciuti, MD; Gonzalo Recondo, MD; Renato Umeton; Giuseppe Lamberti, MD; Mizuki Nishino; Lynette M. Sholl; Michael Cheng; Mark Awad, MD PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| P308 | The impact of obesity on the response rates of checkpoint Inhibitor (CPI) cancer immunotherapy | Philip A. Haddad, MD, MPH; David Sommerhalder, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Solid tumors; Tumor microenvironment |
| P315 | The expression of programmed death ligand 2 (PD-L2) in immunosuppressive tumor microenvironment of non-small cell lung cancer (NSCLC) and its potential association with immunotherapy | Qu Zhang, PhD; Stefan Bentink; Vinay Pawar; Farzad Sekhavati, PhD; Keith E. Steele, DVM, PhD; Jason Hipp; Song Wu, PhD; | Checkpoint Blockade Therapy | Biomarkers; Clinical trial; Gene expression; Immune suppression; T cell; Tumor microenvironment |
| P320 | Novel in vivo preclinical humanized models for the evaluation of human specific immune checkpoint inhibitors | Anya Avrutskaya; Fabienne Sonego; Jacob Hauser; Emily O’Koren; Robin Ball; Gaëlle Martin; Julie Chaix; Thi Bui; Ian Belle; Elizabeth Reap; Patrick Fadden, PhD; Chassidy Hall; Kader Thiam; Paula Miliani de Marval; | Checkpoint Blockade Therapy | Checkpoint blockade; Tumor infiltrating lymphocytes (TILs) |
| P321 | Real-world clinical outcomes among patients with advanced non-small cell lung cancer who initiated first-line regimens | Eric Nadler, MD; Eric Nadler, MD; Bhakti Arondekar, PhD; Kathleen M. Aguilar; Jie Zhou; Jane Chang; Xinke Zhang; Vivek Pawar; | Checkpoint blockade therapy | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Targeted therapy |
| P324 | Pan-tumor analysis of the association of cancer and immune biology-related gene expression signatures with response to pembrolizumab monotherapy | Razvan Cristescu, PhD; Michael Nebozhyn, PhD; Chunsheng Zhang, PhD; Andrew Albright, PhD; Julie Kobie, PhD; Lingkang Huang; Qing Zhao, MD PhD; Anran Wang; Hua Ma; Andrea Webber; Petar Jelinic; Mohini Rajasagi; Sandra C. Souza; Raluca Predoiu; Z. Alexander Cao; Junshui Ma; Michael Morrissey; Clemens Krepler, MD; Stephen Keefe; Jonathan Cheng, MD; Vassiliki Karantza; Sukrut Shah; Rodolfo Perini, MD; Antoni Ribas, MD, PhD; Petros Grivas, MD, PhD; David Cescon; Terrill K. McClanahan, PhD; Alexandra Snyder, MD; Mark Ayers, PhD; Jared Lunceford, PhD; Andrey Loboda, PhD; | Clinical Trial Completed | Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Immune suppression; Solid tumors; Tumor microenvironment; Tumor stroma |
| P325 | Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy. | Bernardo L. Rapoport, MD; Simon Nayler; Jerome Galon, Dr; T Mlecnik; Teresa Smit; Jacqui Barnard-Tidy; Aurelie Fugon; Marine Martel; Ronald Anderson, Professor; Carol Benn; | Clinical Trial Completed | Chemotherapy; Clinical study; Immunoscore; T cell; Tumor infiltrating lymphocytes (TILs) |
| P326 | A Retrospective Analysis of DNA Plasmid and Peptide-Based Vaccine Therapy in Treatment of HER-2/neu+ Breast Cancer | Aaron W. Stewart, BS; William R. Gwin, MD; Mary L. Disis, MD, FACP; Jennifer S. Childs; James Y. Dai; Doreen M. Higgins, RN, BSN, OCN; Angela Kask; | Clinical Trial Completed | Clinical trial; Targeted therapy; Tumor antigens; Vaccine |
| P327 | Evaluation of PD-L1 and cutoff selection to define a predictive biomarker for pembrolizumab monotherapy in esophageal cancer using KEYNOTE-180 | Mary Savage; Serafino Pantano; Qi Liu; Jared Lunceford, PhD; Peter Kang; Pooja Bhagia, MBBS, MD; Kenneth Emancipator, MD; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Solid tumors |
| P328 | A phase IIB study of Pembrolizumab plus BL-8040 in metastatic pancreatic cancer: Clinical outcomes and biological correlates. | David R. Fogelman, MD; Michael Overman, MD; Robert Wolff; Milind Javle, MD; Shubham Pant, MBBS; Gauri Varadhachary; Rachna T. Shroff; Ignacio Wistuba, MD; Carmelia M. Barreto, PhD; Renganayaki K. Pandurengan, MS; Sandesh Subramanya, PhD; Debora A. Ledesma, PhD; Abi Vainstein-Haras, MD; Ella Sorani, PhD; Tzipora M. Lustig; Osnat Kashtan; Yosi Gozlan; Steven M. Townson, PhD; Jeanne M. Fahey, PhD; James Yao, MD; | Clinical Trial Completed | Antibody; Checkpoint blockade; Chemokine; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P329 | PolyPEPI1018 off-the shelf vaccine as add-on to maintenance therapy achieved durable treatment responses in patients with microsatellite-stable metastatic colorectal cancer patients (MSS mCRC) | Joleen M. Hubbard, MD; Chiara Cremolini, MD; Rondell Graham, MD; Roberto Moretto, MD; Jessica Mitchell, CNP; Jaclynn Wessling; Eniko Toke; Zsolt Csiszovszki, PhD; Orsolya Lorincz; Levente Molnár; Eszter Somogyi; Mónika Megyesi; Kata Pántya; József Tóth; Péter Páles; István Miklós; Alfredo Falcone, MD; Joleen M. Hubbard, MD | Clinical Trial Completed | Clinical trial; Solid tumors; Vaccine |
| P330 | Results from the completed dose-escalation of the alloSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients | Hans Prenen, MD; Marika Rasschaert, MD; Alain Hendlisz, MD; Leila Shaza, MD; Erik Alcantar-Orozco, MD, PhD; Emilie Cerf, PhD; Florence Renard; Caroline Lonez, PhD; Anne Flament; Jeroen Dekervel, MD; Eric Van Cutsem, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical study; Solid tumors |
| P331 | Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients | Leila Shaza, MD; Alain Hendlisz, MD; Ahmad Awada, MD, PhD; Jean-Luc Canon, MD; Javier Carrasco; Eric Van Cutsem, MD, PhD; Jeroen Dekervel, MD; Erik Alcantar-Orozco, MD, PhD; Florence Renard; Emilie Cerf, PhD; Caroline Lonez, PhD; Anne Flament; Marc Van den Eynde, MD; Jean-Pascal Machiels, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical study; Solid tumors |
| P332 | Cancer vaccine against prostate cancer antigen TARP induces antigen-specific CD8+ T cells with upregulation of activation marker PD1 in patients with decreased PSA velocity in D0 prostate cancer. | Hoyoung M. Maeng, MD; Brittni Moore; Lauren V. Wood, MD; Seth Steinberg; Katherine McKinnon, MS; Masaki Terabe, PhD; Purevdorj Olkhanud; Ira H. Pastan, MD; Jay A. Berzofsky, MD, PhD; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P333 | Timed anti-tumor vaccination during chemotherapy induces strong T-cell immunity and prolonged survival of late stage cervical cancer patients. | Marij J. Schoenmaekers-Welters, PhD; Marij JP. Welters, PhD; Cornelis J. Melief, MD, PhD; Ignace Vergrote; Judith Kroep, MD, PhD; Gemma G. Kenter, MD,PhD; Nelleke Ottevanger; Wiebren AA. Tjalma; Hannelore Denys; Mariette van Poelgeest, MD, PhD; Hans Nijman; Anna KL. Reyners; Thierry Velu; Frederic Goffin; Roy I. Lalisang; Nikki M. Loof; Sanne Boekestijn; Willem Jan Krebber; Leon Hooftman; Sonja Visscher; Brent A. Blumenstein, PhD; Richard B. Stead; Winald R. Gerritsen; Sjoerd H. van der Burg, PhD; | Clinical Trial Completed | Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P334 | Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study | Christine H. Chung, MD; Marcelo Bonomi, MD; Conor Steuer, MD; Michael Schell; Jiannong Li; Matthew Johnson; Caitlin McMullen; J. Trad Wadsworth; Krupal Patel; Julie A. Kish, MD; Jameel Muzaffar, MD; Kedar Kirtane; James Rocco; Nabil F. Saba, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Targeted therapy |
| P335 | The tumor immune microenvironment and its association with pCR in NRG Oncology/NSABP B-52: Quantification of PD-1, PD-L1, CD8, FOXP3, and CD68 by multiplex fluorescent-immunohistochemistry | Marion E. Joy, PhD; Ying Wang; Rim S. Kim; Nan Song; Ashok Srinivasan; Huichen Feng; Corey Lipchik; Reena S. Cecchini; Samuel A. Jacobs; Joseph P. Costantino; Sandra M. Swain; Eleftherios P. Mamounas; Priya Rastogi; Soonmyung Paik; C. Kent Osborne; Norman Wolmark; Peter C. Lucas; Mothaffar F. Rimawi; Katherine L. Pogue-Geile; | Clinical Trial Completed | Bioinformatics; Checkpoint blockade; Clinical study; Clinical trial; Monocyte/Macrophage; T cell; Tumor microenvironment |
| P336 | Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with acute lymphoblastic leukemia | Amita Kulshrestha; Haneen Shalabi, Do; Vandana Sachdev; Douglas R. Rosing; Stanislav Sidenko; Crystal L. Mackall, MD; Brandon Wiley; Daniel W. Lee; Nirali N. Shah; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Immune monitoring; Pediatric tumors; T cell |
| P337 | Survival prolongation by dendritic cell vaccination in combination with OK-432, gemcitabine and/or S-1 in patients with advanced pancreatic cancer | Masahiro Ogasawara, MD, PhD; Shuichi Ota, MD PhD; | Clinical Trial Completed | Clinical trial; Dendritic cell; Tumor antigens; Vaccine |
| P338 | 2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC) | Fabrice Barlesi, MD, PhD; Mustafa Özgüroglu; Johan Vansteenkiste; David Spigel; James Yang; Hidenobu Ishii; Marina Garassino; Filippo de Marinis; Aleksandra Szczesna; Andreas Polychronis; Ruchan Uslu; Maciej Krzakowski; Jong-Seok Lee; Luana Calabro, MD; Osvaldo Aren Frontera; Barbara Ellers-Lenz; Marcis Bajars; Mary Ruisi; Keunchil Park; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P339 | Survival is improved by antigen-specific cytotoxic T lymphocytes (CTL) responses after treatment with the vaccine Tedopi in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients | Benjamin Besse, MD PhD; Enriqueta Felip, MD PhD; Giuseppe Giaccone; Rafal Dziadziuszko; Elisabeth Quoix, MD; Werner Hilgers; Federico Cappuzzo; Christophe Borg; Jordi Remon; Nicolas Poirier; Dominique Costantini; Bérangère Vasseur; Santiago Viteri; | Clinical Trial Completed | Antigen presenting cells; Biomarkers; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P340 | Region-focused Deep Survival Learning on PD-L1 stained Tissue Samples for Data-driven Stratification of Durvalumab-treated NSCLC Patients | Nicolas Brieu, PhD; Ansh Kapil; Armin Meier, PhD; Keith E. Steele, DVM, PhD; Marlon C. Rebelatto, DVM, PhD, DACVP; Guenter Schmidt, PhD; | Clinical Trial Completed | Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture |
| P341 | Activation of toll-like receptors via PS-targeting monoclonal antibodies | Rolf A. Brekken, PhD; | Clinical Trial Completed | Angiogenesis; Antibody; Checkpoint blockade; Clinical study; Immune adjuvant; Immune suppression; MDSC; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P342 | Long term outcomes of a Phase I Study with UV1, a Second Generation Telomerase Based Vaccine, in Patients with advanced Non-Small Cell Lung Cancer | Wenche Rasch, PhD; Paal F. Brunsvig, MD PhD; Martha Nyakas, MD; Clau Reisse, MD; Jon Amund Kyte; Hedvig Vidarsdotter Juul; Steinar Aamdal; Gustav Gaudernack, PhD; Else Marit Inderberg; | Clinical Trial Completed | Clinical study; Immune monitoring; Solid tumors; Tumor antigens; Vaccine |
| P343 | Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab | Julio Peguero, MD; Enriqueta Felip, MD PhD; Bernard Doger; Margarita Majem; Enric Carcereny; Tim Clay; Pawan Bajaj; Matthew G. Krebs, MD PhD; Frederic Triebel, MD, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Dendritic cell; Monocyte/Macrophage |
| P344 | A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L)1 directed therapy: ETCTN 10021 | Arta M. Monjazeb, MD, PhD; Anita Giobbie-Hurder, MS; Ana Lako; Mark Awad, MD PhD; Ryan D. Gentzler, MD; Carrie Lee; Joleen Hubbard; James L. Abbruzzese, MD; Salma K. Jabbour, MD; Nataliya Uboha; Kevin Stephans; Jennifer Johnson, MD; Haeseong Park; Liza C. Villaruz, MD; Katrina Kao; Elad Sharon, MD, MPH; David Raben, MD; Raymond Mak; Howard Streicher, MD; Helen Chen, MD; Mansoor M. Ahmed, PhD; Scott J. Rodig, MD, PhD; F. Stephen Hodi, Jr., MD; Jonathan Schoenfeld, MD, MPH; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Radiotherapy |
| P345 | PARP inhibition when combined with PD-L1 inhibition has a suppressive effect on T cells in patients with relapsed or recurrent small cell lung cancer | Nobuyuki Takahashi, MD, PhD; Vinodh N. Rajapakse; Min-Jung Lee; Akira Yuno; Sunmin Lee; Sehyun Kim; Rasa Vilimas; Samantha Nichols; Jane B. Trepel; Anish Thomas; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P346 | Comparison of TMEs from melanoma and NSCLC patients refractory or resistant to anti–PD-(L)1 therapies | George Locke; Cherie Taglienti, PhD; Laureen S. Ojalvo; Christoph Helwig, MSc; Alex Rolfe; Olaf Christensen; Isabelle Dussault, PhD; Isabelle Dussault, PhD; | Clinical Trial Completed | Antibody; Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Immune suppression; T cell; Tumor antigens; Tumor microenvironment |
| P347 | Immunomodulation in tumor and peripheral blood following Toca 511 & Toca FC treatment in patients with solid tumors | Gerald S. Falchook, MD; Jordi Rodon; Shree Venkat; Arthur Donahue; Peder Horner; Amber Thomassen; William Accomando; Maria Rodriquez-Aguirre; Cornelia Bentley; Daniel Hogan; Derek Ostertag; Sharon Yavrom; Thian Khoeh; Douglas Jolly, PhD; Harry Gruber, MD; Jolene S. Shorr; Jaime Merchan; | Clinical Trial Completed | B cell; Clinical trial; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P348 | A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies | Aparna Hegde, MD; Priyamvada Jayaprakash, PhD; Elizabeth Sumner; Di Nguyen; Hira Zain; Sarina A. Piha-Paul, MD; Daniel Karp; Jordi Rodon; Shubham Pant, MBBS; Siqing Fu, MD, PhD; Ecaterina I. Dumbrava, MD; Timothy A. Yap, MD PhD; Vivek Subbiah, MD; Priya Bhosale, MD; Jack P. Higgins, PhD; Eric T. Williams; Thomas F. Wilson; Funda Meric-Bernstam, MD; Michael A. Curran, PhD; David S. Hong, MD; | Clinical Trial Completed | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; MDSC; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P349 | Effects of bintrafusp alfa (M7824) and radiation combination therapy on antitumor activity, immune response, and radiation-induced fibrosis in multiple cancer models | Yan Lan, MD; Chunxiao Xu, PhD; Huakui Yu; Guozhong Qin; Bo Marelli; Jin Qi; Rachel E. Fontana; Amit Deshpande; George Locke; Alex Rolfe; Molly H. Jenkins; Joern-Peter Halle; Kin-Ming Lo; | Clinical Trial Completed | Antibody; Checkpoint blockade; Gene expression; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P350 | Clinical Signal/Profile in a Phase I Study of T-Cell Receptor (TCR) Affinity-Enhanced Specific T-Cells (TAEST) in Advanced Cancer Patients | Zhaosheng Han, MD, PhD; Xing Zhang, MD; Jian Zhang; Chengzhi Zhou; Haiping Gong; Desheng Weng, MD; Jianchuan Xia, PhD MD; Johnson YN. Lau; Shiyue Li; Weiliang Zhu; Zhaosheng Han, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; Clinical study; Clinical trial; T cell; Tumor antigens |
| P351 | Association between response assessment using RECIST and irRECIST in 1765 patients with advanced solid tumors treated with avelumab monotherapy | Juliane Manitz, PhD; Julian Manitz; Peter Eggleton; Marcis Bajars; Oliver Bohnsack, MD, PhD, MBA; James L. Gulley, MD, PhD, FACP; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P352 | Workflow for Immune Monitoring during Clinical Trials by using unsupervised high dimensional augmented intelligence assisted analysis | Alessandra Metelli, PhD; Carsten Krieg, PhD; Luis E. Cardenas, BS.; Alessandra Metelli, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical study |
| P353 | Phase 1 pilot study of RRx-001 + nivolumab in advanced metastatic cancer (PRIMETIME) | Corey A. Carter, MD; Bryan Oronsky, MD PhD; Mary Quinn; Jane Trepel; Nacer Abrouk, PhD; Jeff Skinner, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Coinhibition; Costimulation; Immune adjuvant; Immune suppression; Immune toxicity; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell |
| P354 | Exploring correlates of clinical and immune response to cancer immunotherapy using FAUST, a novel unbiased cell population discovery method, in whole blood flow cytometry | Steven P. Fling, PhD; Nirasha Ramchurren, PhD; Leonard D'Amico; Martin A. Cheever, MD; Evan Greene; Greg Finak; Raphael Gottardo, PhD; | Clinical Trial Completed | Biomarkers; Clinical study; Immune monitoring; Myeloid cells; T cell; Tumor antigens; Vaccine |
| P355 | Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignancies | Alexander I. Spira, MD, PhD, FACP; Morris D. Groves; Aaron Hansen; Wael A. Harb; Kelly K. Curtis, MD; Erina Koga-Yamakawa; Makoto Origuchi; Zhonggai Li; Jose Iglesias; Walid L. Shaib, MD; Alexander I. Spira, MD, PhD, FACP; | Clinical Trial Completed | Clinical study; Clinical trial; Leukemia/Lymphoma; Solid tumors |
| P357 | Phase I/II clinical and immune responses for locally advanced or metastatic pancreatic cancer using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) | Lawrence G. Lum, MD, DSc; Tri Le; Minsig Choi; Archana Thakur, PhD; Matthew Reilly; Paul R. Kunk, MD; Abhinav Deol, MD; Karen Ballen, MD; Tamila Kindwall-Keller, DO; Dana L. Schalk; Ewa Kubicka; Manley Huang, PhD; Philip A. Philip, MD; Hussein Aoun; Gregory Dyson, PhD; Qin Liu; Anthony F. Shields, MD PhD; | Clinical Trial Completed | Adoptive immunotherapy; Antibody; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P358 | Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma | Sandra P. D'Angelo, MD; George Demetri; Brian Van Tine, MD, PhD; Mihaela Druta; John Glod, MD; Warren Chow; Jenna Tress; M. Phillip DeYoung; Aisha N. Hasan, MBBS MD; Yuehui Wu; David C. Turner; Ran Ji; Alexandra Gyurdieva; Dejka Araujo, MD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Clinical trial; Gene expression; T cell |
| P359 | Tracking and profiling of NY-ESO-1 TCR-transgenic T cells upon adoptive transfer in patients with NY-ESO-1-expressing solid tumors: in vivo differentiation associated with response | Michael Fehlings; Alessandra Nardin, DVM; Faris Kairi; Evan Newell, PHD; Yoshihiro Mihayara; Shinichi Kageyama; Hiroshi Shiku, MD; | Clinical Trial Completed | Adoptive immunotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell; Tumor antigens |
| P360 | The Influence of Durvalumab/Tremelimumab Combination Therapy on Sarcomas Immune Microenvironment Profile in a Phase II clinical trial (NCT02815995) | Edwin R. Parra, MD., PhD; Carmelia M. Barreto, PhD; Ruth Salazar, MD; Cara Haymaker, PhD; Heather Lin; Carmen Behrens, MD; Mei Jiang; Luisa Solis, MD; Krishna R. Pandurenga, MS; Sandesh Subramanya, PhD; Young U. Kim, PhD; Chantale Bernatchez; Jack Lee, PhD; Taylor Tate; Teresa Simmons; Alexander J. Lazar, MD, PhD; Wei-Lien Wang; Zachary A. Cooper, PhD; Jaime Rodriguez-Canales, MD; Jean C. Soria, MD; Anthony P. Conley, MD; Ignacio Wistuba, MD; Neeta Somaiah, MD, MBBS; | Clinical Trial Completed | Clinical trial; Immune contexture; Immune tolerance; Immunoscore; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P361 | Molecular and Immunologic Profiling of CD8+ T Cell Responses in Patients Receiving a Multiple Antigen-Engineered Dendritic Cell Vaccine | Juraj Adamik, PhD; Patricia M. Santos, PhD; Samuel Du, BS; Lazar Vujanovic, PhD; Timothy Howes; Sarah Warren, PhD; Andrea Gambotto, MD; John M. Kirkwood, MD; Lisa H. Butterfield, PhD; | Clinical Trial Completed | Antigen presenting cells; Checkpoint blockade; Clinical trial; Dendritic cell; Gene expression; Immune adjuvant; Immune monitoring; T cell; Tumor antigens; Vaccine |
| P362 | First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: primary analysis after ≥15 months of follow-up from JAVELIN Merkel 200, a registrational phase 2 trial | Sandra P. D'Angelo, MD; Celeste Lebbé; Laurent Mortier; Andrew S. Brohl, MD; Nicola Fazio; Jean-Jacques Grob; Natalie Prinzi; Glenn Hanna; Jessica C. Hassel, MD; Felix Kiecker; Barbara Ellers-Lenz; Marcis Bajars; Meliessa Hennessy, MPH; Paul Nghiem, MD, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Solid tumors |
| P364 | A gp100 targeting TCR-based soluble T cell engaging bispecific induces mobilisation and activation of peripheral T cells in patients with metastatic melanoma | Sion M. Lewis, BSc MSc PhD; Mariantonella Vardeu; Jacob Hurst, PhD; Cheryl McAlpine, MSN; | Clinical Trial Completed | Biomarkers; Chemokine; Clinical study; Immune monitoring; Solid tumors; T cell; T cell lineages |
| P365 | A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63) | Craig L. Slingluff, Jr., MD; Gina R. Petroni, PhD; Kimberly A. Chianese-Bullock, PhD; Nolan A. Wages, PhD; Walter C. Olson, PhD; Kelly T. Smith; Lynn T. Dengel, MD; Anna Dickinson; Caroline Reed; Elizabeth M. Gaughan, MD; William W. Grosh, MD; Varinder Kaur, MD; Nikole Varhegyi; Mark E. Smolkin; Nadejda V. Galeassi; Donna H. Deacon, BS; | Clinical Trial Completed | Antibody; Clinical trial; Immune adjuvant; Solid tumors; T cell; TLR; Tumor antigens; Vaccine |
| P366 | A phase 1 study of NY-ESO-1 vaccine + ipilimumab (ipi) in patients with unresectable or metastatic melanoma | Craig L. Slingluff, Jr., MD; Hassane M. Zarour, MD; Michael Postow, MD; Philip Friedlander, MD PhD; Craig E. Devoe, MD; Ileana S. Mauldin, PhD; Kelly T. Smith; Mary Macri, BSc; | Clinical Trial Completed | Antibody; Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment |
| P367 | A multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in post-resection melanoma patients at high risk of recurrence. | Craig L. Slingluff, Jr., MD; Brent A. Blumenstein, PhD; Karl D. Lewis, MD; Robert H. Andtbacka, MD, CM, FACS, FRCSC; John Hyngstrom, MD; Mohammed Milhem, MBBS; Svetomir N. Markovic, MD, PhD; Omid Hamid, MD; Leonel Hernandez-Aya, MD PhD; Tawnya Bowles, MD; Prejesh Philips, MD; Joel Claveau, MD; Sekwon Jang, MD; Jose Lutzky, MD, FACP; Anna Bar, MD; Peter Beitsch, MD; | Clinical Trial Completed | Clinical trial; Solid tumors; Vaccine |
| P368 | ZI-H04 - A novel MHC class II restricted TCR based cellular therapy targeting hTERT to treat solid tumours | Jens-Peter Marschner, MD; Mona Welschof, PhD; Miguel Forte; Eva Kristine Klemsdal; Sylvie Pollmann; Namir Hassan; Inês Cardoso, PhD | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P369 | Feasibility of a phase I personalized adoptive T-cell therapy in patients with relapsed/refractory solid tumors | Apostolia M. Tsimberidou, MD, PhD; Ali Mohamed; Stephen L. Eck, MD, PhD; Harpreet Singh; Patrick Hwu, MD; Cassian Yee, MD; Borje Andersson, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Biomarkers; Clinical trial; Solid tumors; T cell |
| P370 | The positive correlation between baseline absolute eosinophil count (AEC) in blood and clinical benefit to PD-(L)1 inhibition monotherapy | Danni Yu, PhD; Anna M. Szpurka, PhD; Michelle Carlsen; Danni Yu, PhD; Antoine Hollebecque, MD; Hyun Cheol Chung, MD, PhD; Amita Patnaik; Johanna Bendell, MD; Antoine Italiano, MD; Yung-Jue Bang, MD PhD; Chia-Chi Lin, MD, PhD; Marcus O. Butler, MD; Timothy A. Yap, MD PhD; María José de Miguel, MD; María José de Miguel, MD; Jean-Pascal Machiels, MD, PhD; Marc Peeters, MD, PhD; Wu-Chou Su, MD; Victor Moreno, MD; Yumin Zhao, PhD; Erik Rasmussen, PhD; Xiaojian Xu, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors |
| P371 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | John Lynes, MD; Victoria Sanchez; Anthony Nwankwo; Gifty A. Dominah; Xiang Wang, MS; Isac Kunnath; Samantha Dill; Gretchen K. Scott; Christi Hayes; Tianxia Wu; Marta Penas-Prado; Jing Wu; Eric Burton; John Heiss; Christopher S. Hourigan, MD, PhD; Mark R. Gilbert; Edjah K. Nduom, MD; John Lynes, MD; Edjah K. Nduom, MD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Immune monitoring; Immune suppression; Proteomics; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P372 | Circulating Immune Cell Biomarkers Predict Response to Immune Checkpoint Inhibitor Therapy in Metastatic Breast Cancer | Jin Sun L. Bitar, MD; Colt Egelston, PhD; Susan Yost; Wanqiu Hou; Padam Simran; Paul Frankel, PhD; Mina Sedrak; Jana Portnow, MD; Joanne Mortimer, MD; Christina Yeon, MD; Arti Hurria, MD; Aileen Tang; Norma Martinez; Peter P. Lee, MD; Yuan Yuan; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; T cell; Tumor microenvironment |
| P373 | A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1) | Luis Manso; Patricia Villagrasa; Nuria Chic; Juan M. Cejalvo; Yann Izarzugaza; Blanca Cantos; Salvador Blanch; Manel Juan; Blanca Gonzalez; Rita Laeufle; Gerard Nuovo; Grey A. Wilkinson, PhD; Matt Coffey; Azucena Gonzalez; Patricia Galvan; Laia Paré; Jordi Canes; Xavier Gonzalez; Aleix Prat, MD PhD; Aleix Prat, MD PhD; Joaquín Gavilá; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P374 | TCR repertoires from peripheral blood correlate with prognostic response in TNBC cancer vaccine immunotherapy | Sadanand Vodala, PhD; Andrew Nguyen, PhD; Noe Rodriguez; Peter Sieling; Charles J. Vaske; Jon Van Lew; kayvan Niazi; John H. Lee, MD; Patrick Soon-Shiong, MD, FRCS, FACS; Shahrooz Rabizadeh; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Immune suppression; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P375 | Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC) | Daniel V. Catenacci, MD; Minori Rosales; Jon M. Wigginton, MD; Hyun Cheol Chung, MD, PhD; Harry Yoon; Lin Shen; Yoon-Koo Kang; Markus Moehler; | Clinical Trial In Progress | Adoptive immunotherapy; Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Tumor antigens |
| P376 | NOUS-209: A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Anna Gorrasi, PhD; Elisa Scarselli; Maria Teresa Catanese; Cinzia Traboni; Paola Antonini; Denis Brkic; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P377 | Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with pembrolizumab in patients with metastatic colorectal or gastric cancer. | Keun-Wook Lee, MD; Young Suk Park, MD, PhD; Joong Bae Ahn; Sun Young Rha; Hark Kyun Kim; Park Young Lee; Min-Hee Ryu; Jeeyun Lee, MD, PhD; Jin Kyung Lee; Sunjin Hwang; Seong-Jin Kiim; Tae Won Kim, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Tumor microenvironment; Tumor stroma |
| P378 | Phase II Study of Combination Ipilimumab, Nivolumab, and Panitumumab in Patients with KRAS, NRAS, and BRAF Wild-Type (WT) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | Michael S. Lee, MD; Patrick J. Loehrer, MD; Iman Imanirad, MD; Stacey Cohen, MD; Kristen Ciombor, MD; Cheryl A. Carlson, MD/PhD; Hanna K. Sanoff, MD; Autumn J. McRee, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P379 | Title: Phase 1 Safety Study in Healthy Volunteers of AB680, a Small-Molecule Inhibitor of CD73 and Rationale for Combination Therapy in Patients with Gastrointestinal Malignancies | Devika Ashok, PhD; Irene Luu; Akshata Udyavar, Ph.D; Lixia Jin; Lijuan Fu; Elaine Ginn; Ken Lawson; Jenna Jeffrey, PhD; Manmohan R. Leleti, PhD; Jay P. Powers, PhD; Eric Connor; Andy Pennell; Daniel DiRenzo, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Amanda Garofalo; Wade Berry, BA; Matthew J. Walters, PhD; Steve W. Young, PhD; Fangfang Yin, PhD; Dominic Lai; Lisa Seitz, MA; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Clinical study; Clinical trial; Immune suppression; Tumor microenvironment |
| P380 | Phase 1b/2 study of BXCL701, a small molecule inhibitor of dipeptidyl peptidases, with bempegaldesleukin (bempeg, NKTR-214) and avelumab (anti-PD-L1) in unresectable or metastatic pancreatic cancer | Louis M. Weiner, MD; Benjamin A. Weinberg, MD; Stina Singel; Cedric Burg; Diane Healey; Jonathan Zalevsky, PhD; Chetan Lathia; Willem W. Overwijk, PhD; Cristian Massacesi; Joyce Acbay; John MacDougall, PhD; Vincent O'Neill; | Clinical Trial In Progress | Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Cytokine; Monocyte/Macrophage; Solid tumors; Tumor microenvironment; Tumor stroma |
| P381 | Phase 1b/2 study of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (anti-PD-1) monoclonal antibody, in small cell neuroendocrine prostate cancer (SCNC, NEPC) | Diane Healey; Rahul Aggarwal, MD; Vincent O'Neill; Cedric Burg; Jiaoti Huang; Johann S. De Bono, MD; Eric J. Small; | Clinical Trial In Progress | Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Cytokine; Monocyte/Macrophage; Solid tumors; Tumor microenvironment; Tumor stroma |
| P382 | KEYNOTE-365 cohort D: phase 1b/2 study of pembrolizumab plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer | Leonard J. Appleman, MD, PhD; Josep Piulats; Nataliya Mar; José A. Arranz; Anthony Joshua, MD; Tina M. Mayer; Neal Shore, MD; Haiyan Wu, PhD; Charles Schloss; Evan Y. Yu; | Clinical Trial In Progress | Clinical trial |
| P384 | A phase I dose escalation and expansion study of HPN424, a PSMA-targeting T cell engager, in patients with advanced prostate cancer refractory to androgen therapy | Johanna Bendell, MD; Mark Stein, MD; Johann de Bono, MD; Richard Austin, PhD; Sue Hirabayashi; Che-Leung Law, PhD; Bryan Lemon, PhD; Holger Wesche, PhD; Aaron Weitzman, MD FACP; Lawrence Fong, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P385 | Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-641 study | Julie Nicole Graff; Joseph Burgents; Li Wen Liang; Arnulf Stenzl; | Clinical Trial In Progress | Clinical trial |
| P387 | A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer (PORTER) | Leo Nissola, MD; Karen Autio, MS, MD; Nina Bhardwaj, MD, PhD; Matthew D. Galsky, MD; Kristopher Wentzel, MD; Vanessa M. Lucey; Cheryl Selinsky, PhD; Christopher Perry; Christopher Cabanski, PhD; Ari J. Bitton; Justin Fairchild; Christine E. Horak, PhD; Jeffrey M. Skolnik, MD; Michael Yellin, MD; Ute Dugan, MD, PhD; Ramy Ibrahim, MD; Lawrence Fong, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune tolerance; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P388 | Pembrolizumab plus docetaxel and prednisone for enzalutamide- or abiraterone acetate–pretreated patients with metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-921 study | Neal Shore, MD; Daniel P. Petrylak, MD; Mostefa Bennamoun; Raffaele Ratta; Josep Piulats; Ben Li; Charles Schloss; Karim Fizazi; | Clinical Trial In Progress | Clinical trial |
| P389 | A Phase I Trial of Interleukin-2 (IL-2) and Pembrolizumab (Pembro) Combination Therapy for Patients with Advanced Renal Cell Carcinoma | Scott S. Tykodi, MD, PhD; Johanna Whitney; Sumia Dakhil; Eleanor L. Bergren; Vivian T. Nguyen; Samantha M. Kiriluk; Shailender Bhatia, MD; John A. Thompson, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P390 | Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study | Evan Y. Yu; Se Hoon Park; Yi-Hsiu Huang; Mostefa Bennamoun; Lu Xu; Jeri Kim; Emmanuel S. Antonarakis, MD; | Clinical Trial In Progress | Clinical trial |
| P391 | Randomized phase II trial of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed stage III or IV ovarian cancer | Lisa A. Abaid, MD; Richard L. Friedman, MD, PhD; John V. Brown, MD; Alberto A. Mendivil, MD; Tiffany L. Beck, MD; Bradley R. Corr; Leslie M. Randall; James R. Mason; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD, FACP; | Clinical Trial In Progress | Clinical trial; Dendritic cell; Neoantigens; Stem cell/cancer-initiating cell; Tumor antigens; Vaccine |
| P392 | Phase 1 combination study of the CHK1 inhibitor prexasertib (LY2606368) and anti-PD-L1 antibody LY3300054, in patients with high-grade serous ovarian cancer and other advanced solid tumors | Khanh T. Do; Claire Manuszak; Sarah E. Kelland; Allison P. Powers; Adrienne Anderson; Alona Muzikansky; Andrew Wolanski; Mariano Severgnini, MSc; Geoffrey Shapiro, MD, PhD; Khanh T. Do, MD; | Clinical Trial In Progress | Biomarkers; Clinical trial; Solid tumors; Targeted therapy; Tumor antigens |
| P393 | Single agent activity of a novel PD-1 inhibitor AGEN2034 in recurrent ovarian cancer. Subset analysis of phase I dose escalation NCT03104699 study | David M. O'Malley; John Hays; Charles Drescher; Jasgit Sachdev; Wilberto Nieves-Neira; Breelyn Wilky; Marylin Huang; Kathleen N. Moore; Waldo Ortuzar; Anna Wijatyk; Hagop Youssoufian; Remigiusz Kaleta, MD; Inbal Sapir; Christopher Dupont, PhD; Irina Shapiro; Debra Richardson, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Immune contexture; Solid tumors; Targeted therapy |
| P394 | A Phase 1 study of INCMGA00012, a PD-1 inhibitor, in patients with advanced solid tumors: Preliminary results for patients with advanced cervical cancer (POD1UM-101) | Janice J. Mehnert, MD; Luis Paz Ares, MD, PhD; Joanna Pikiel, Dr n. med.; Udai Banerji, PhD; Anna Kryzhanivska, MD; Nehal Lakhani, MD, PhD; Sebastian Ochsenreiter, Dr. med.; Tobias Arkenau, MD, PhD; Nawel Bourayou, MD; Deanna Kornacki, PhD; Chuan Tian, PhD; Thomas Condamine, PhD; Itziar Gardeazabal González; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Solid tumors |
| P395 | Phase 2/3 open-label trial of enoblituzumab in combination with MGA012, with and without chemotherapy, in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma | Fernanda I. Arnaldez; Charu Aggarwal, MD MPH; Scott Currence; Jan Baughman, MPH; Paul Moore, PhD; George R. Blumenschein, Jr., MD; Jon M. Wigginton, MD; Robert L. Ferris, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P396 | A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults with Head and Neck Cancer | Ezra Cohen, MD; Robert L. Ferris, MD, PhD; Douglas Adkins, MD; Dan P. Zandberg, MD; Arkadiusz Dudek, MD, PhD; Matthen Mathew; Lara Dunn, MD; Juneko E. Grilley-Olson, MD; Ammar Sukari, MD; Rebecca Redman, MD; Julie E. Bauman, MD, MPH; John M. Kaczmar, MD; Lisle Nabell, MD; Nabil F. Saba, MD; Eric Nadler, MD; Young J. Kim, MD; Ranee Mehra, MD; Nitya Nair, PhD; Somayeh Honarmand, MS; Richard E. Cutler Jr.; Barbara A. Burtness, MD; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical trial; Immune adjuvant; T cell |
| P397 | Interim analysis of the combination of durvalumab and cetuximab in a phase II trial of patients with recurrent and metastatic head and neck squamous cell carcinoma. | Shuchi Gulati, MD; Sarah Palackdharry; Layne Weatherford; Sarah Wilson; Shireen Desai; Aubrey Steele; Kashif M. Riaz; Vinita Takiar; Trisha W. Draper; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; NK/NK T cell; Solid tumors; Targeted therapy |
| P398 | miRNA-A and programmed death ligand 1 (PD-L1) expression in oral squamous cell carcinoma | Hong J. Hyung, MD. PhD; Yoon Ho Ji. Ko; Lee Hee JIn; Sang Hoon Jeon; | Clinical Trial In Progress | Immune suppression; Tumor microenvironment |
| P399 | Instructive conclusions from performing immune correlatives on IO trials: a meta-analysis of patient tumor and blood samples. | Patrick Lizotte, PhD; Megan Cavanaugh; Melissa Jean; Cloud Paweletz, PhD; | Clinical Trial In Progress | Checkpoint blockade; Immune monitoring |
| P400 | Sitravatinib and Nivolumab for resectable Oral cavity squamous cell carcinoma Window of opportunity study (SNOW) | Marc Oliva Bernal, MD; Douglas Chepeha, MD; Amy AP. Prawira, MD; Anna Spreafico, MD PhD; Scott Bratman, MD; Tina Shek, MD; John De Almeida, MD; Ivan Yeung, MD; Aaron Hansen; Andrew Hope, MD; David Goldstein, MD; Ralph Gilbert, MD; Doug Vines, BSc, MRT(N), CNMT; Patrick Gullane; Dale H. Brown, MD; Ilan Weinreb, MD; Bayardo Perez-Ordoñez, MD; Trevor Pugh, PhD; Pamela S. Ohashi, PhD; Ben Wang, PhD; Jonathan Irish, MD; Hirak Der-Torossianh, MD; Isan Chen, MD; Lillian Siu, MD; | Clinical Trial In Progress | Angiogenesis; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P401 | Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC): the phase 3 KEYNOTE-689 study | Ravindra Uppaluri, MD, PhD; Nancy Y. Lee, MD; William Westra; Ezra Cohen, MD; Robert I. Haddad; Stephane Temam; Christophe Le Tourneau; Rebecca Chernock; Sufia Safina; Arkadiy Klochikhin; Amichay Meirovitz; Irene Brana, MD; Joy Yang Ge; Ramona F. Swaby, MD; Cecilia Pinheiro; Douglas Adkins, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant; Radiotherapy |
| P402 | BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma | Michael R. Bishop, MD; Ian Flinn, MD; Peter Borchmann; Ulrich Jaeger; Jason R. Westin, MD; Nada Hamad; Duncan Purtill; Richard Greil; Simone Thomas; Takanori Teshima; Hideo Harigae; Carlos G. Garcia; Pere Barba; Abhinav Deol, MD; Paul Shaughnessy; Jessie Gu; Giovanna Andreola; Marcela Martinez Prieto; Lida Pacaud; Stephen J. Schuster, MD; | Clinical Trial In Progress | CAR T cells; Clinical trial; Leukemia/Lymphoma |
| P403 | Serum soluble CD25 may predict the early therapeutic response in pediatric patients with B-cell non-Hodgkin's lymphoma（B-NHL）during autologous chimeric antigen receptor T cell(CAR-T) therapy | Jing X. Guo; Yonghong Zhang, Professor; Juan Du, MD; Juan Du, MD; | Clinical Trial In Progress | B cell; CAR T cells; Clinical study; Cytokine; Leukemia/Lymphoma; Pediatric tumors |
| P404 | Developing canine CART-19 to fully leverage comparative oncology and inform human clinical trials | Kumudhini P. Haran, M.S; Ailian Xiong; Enrico Radaelli; Patrick J. Savickas; Avery Posey; Donald Siegel; Nicola Mason, B.Vet Med PhD; | Clinical Trial In Progress | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma |
| P405 | CASSIOPEIA: A phase 2 study evaluating efficacy and safety of tisagenlecleucel in first-line therapy for high-risk pediatric and young adult patients with B-ALL who are MRD positive at the EOC | Shannon L. Maude, MD, PhD; Hunger Stephen, MD; Jochen Buechner, MD; Stephen A. Grupp, MD; Susana Rives; Andre Baruchel; John Levine; Joerg Krueger; Theodore W. Laetsch; Marianne RS. Ifversen; Aiesha Zia; Jaclyn Davis; Eric Bleickardt; Mignon Loh; | Clinical Trial In Progress | B cell; CAR T cells; Clinical trial; Leukemia/Lymphoma; T cell |
| P406 | Interleukin-1 blockade to prevent severe immune effector cell-associated neurotoxicity syndrome; Trial in progress | Caspian Oliai, MD; Anna Crosetti; John M. Timmerman, MD | Clinical Trial In Progress | CAR T cells; Cytokine; Inflammation; Leukemia/Lymphoma |
| P407 | Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation | Masatoshi Kudo, MD, PhD; Andrew Zhu; Arndt Vogel; Thomas Yau; Jian Zhou; Erluo Chen; Usha Malhotra; Abby Siegel; Ann-Lii Cheng, MD PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant; Solid tumors |
| P408 | LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma | Josep M. Llovet; Masatoshi Kudo, MD, PhD; Ann-Lii Cheng, MD PhD; Richard Finn; Peter Galle; Shuichi Kaneko, MD PhD; Tim Meyer; Shukui Qin; Corina E. Dutcus; Erluo Chen; Leonid Dubrovsky; Abby Siegel; Andrew Zhu; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Targeted therapy |
| P409 | A case report of personalized neoantigen peptide vaccine in treating patients with biliary tract cancer | Fang Yong; Fan Mo; Jiawei Shou; Huimin Wang; Lin Chen; Shanshan Zhang; Hongsen Li; Weidong Han; Hongming Pan; Shuqing Chen; | Clinical Trial In Progress | Bioinformatics; Clinical trial; Neoantigens; Solid tumors; Vaccine |
| P410 | Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with durvalumab in patients with advanced non-small cell lung cancer (NSCLC) | Ji-Youn Han, MD, PhD; Kyoung-Ho Pyo; Jea Hwan Kim; Chun-Feng Xin; Jin Kyung Lee; Sunjin Hwang; Seong-Jin Kim; Byoung Chul Cho, MD.phD; Byoung Chul Cho, MD.phD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P411 | Treating advanced non-small lung cancer (NSCLC) patients after checkpoint inhibitor treatment failure with a novel combination of Viagenpumatucel-L (HS-110) plus nivolumab | Daniel Morgensztern, MD; Saiama Waqar, MD; Lyudmila Bazhenova, MD; Rachel E. Sanborn, MD; Lori Mcdermott, RN, MSc; Jeff Hutchins, PhD; Luis E. Raez, MD, FACP, FCCP; Corey J. Langer, MD; Roger Cohen, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma; Vaccine |
| P412 | Validation of a Single-Blinded (Patients Only) Study Design for the Prevention of Premature Patient Consent Withdrawal in the Immuno-Oncology Trial DUBLIN-3 | Ramon Mohanlal, MD, PhD, MBA; Huang Lan, PhD; Ramon Mohanlal, MD, PhD, MBA; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Dendritic cell |
| P413 | A Phase 1b/2 study of galunisertib in combination with nivolumab in solid tumors and NSCLC | Ernest Nadal, MD, PhD; Mansoor N. Saleh, MD; Santiago Ponce Aix, MD; Maria Ochoa de Olza; Sandip P. Patel, MD; Scott J. Antonia, MD, PhD; Yumin Zhao, PhD; Ivelina Gueorguieva, PhD; Michael Man, PhD; Shawn T. Estrem, PhD; Emin Avsar; Wen Hong Lin; Karim Benhadji; Susan Guba; Inmaculada Ales Diaz; Ernest Nadal, MD, PhD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune suppression; Solid tumors |
| P414 | Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced non-small cell lung cancer patients | Michael Shafique, MD; Terrence L. Fisher, Jr., PhD; Elizabeth E. Evans, PhD; John E. Leonard, MD PhD; Desa Rae Pastore; Crystal Mallow, BS; Ernest S. Smith, PhD; Andreas Schroeder, MD, PhD; Kevin Chin; Joseph Beck; Megan A. Baumgart, MD; Ramaswany Govindan, MD; Nashat Y. Gabrail, MD; Jonathan W. Goldman, MD; Rachel E. Sanborn, MD; Alexander I. Spira, MD, PhD, FACP; Nagashree Seetharamu; Yanyan Lou, MD; Aaron Mansfield, MD; Maurice Zauderer, PhD; PhD; Terrence L. Fisher, Jr., PhD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Immune monitoring; Myeloid cells; MDSC; Regulatory T cell (Treg cell); Tumor microenvironment |
| P415 | Tumor Treating Fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in Phase 3 LUNAR Study | Uri Weinberg, MD PhD; Ori Farber; Moshe Giladi; Ze'ev Bomzon; Eilon D. Kirson; Uri Weinberg, MD PhD; Uri Weinberg, MD PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Coinhibition; Solid tumors |
| P416 | A phase 1 dose escalation with expansion study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AMV564 in subjects with advanced solid tumors | Raghad M. Abdul Kairm, MD; Anthony Tolcher, MD; Victoria Smith; Sterling C. Eckard, PhD; Jeanmarie Guenot; Patrick Chun; | Clinical Trial In Progress | Clinical trial; Immune suppression; Myeloid cells; MDSC; Solid tumors; T cell; Targeted therapy |
| P417 | ATLAS™ identifies relevant neoantigens for therapeutic anti-tumor vaccination and may serve as a biomarker for efficacy of immunotherapy of solid tumors | Parul Agnihotri; Tulin Dadali; Parul Agnihotri, PhD; | Clinical Trial In Progress | Antigen presenting cells; Biomarkers; Clinical study; Clinical trial; Dendritic cell; Neoantigens; Solid tumors; T cell; Targeted therapy; Vaccine |
| P418 | Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis | Pablo Fernandez-Penas, MD, PhD; Matteo S. Carlino, MBBS, PhD, BMedSC, F; Victoria Atkinson, MD; Melinda Telli; Rohit Joshi; Sajev Thomas; Katy Tsai, MD; Rachel Roberts-Thomson; Andrew Haydon, MBBS PhD; Andrew Mant; Tom Van Hagen; Katharine Cuff; Bianca Devitt; Igor Puzanov, MD, MSCI, FACP; Marcus O. Butler, MD; Catalin Mihalcioiu; Hatem Soliman, MD; John Hyngstrom, MD; Mecker Moller; Gregory A. Daniels, MD, PhD; Eric D. Whitman, MD, FACS; Erica Browning, BS; Reneta Hermiz; Lauren Svenson; Jack Y. Lee; Donna Bannavong; Jendy Sell; Kellie Malloy; David A. Canton, PhD; Christopher G. Twitty; Adil Daud, MBBS MD; Alain Algazi, MD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; Immune monitoring; MDSC; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P419 | A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC) | Johanna Bendell, MD; Drew Rasco, MD; Wungki Park, MD; Lei Zhou, MD, MS; Anna Galkin, PhD; Debbie Slee, PhD; Laura L. Carter, PhD; David Nickle, PhD; Rebecca Tran, MS; Jack Li, PhD; Beatrice Ferguson, MS; Jakob Dupont, MD; Vineet Gupta, PhD; Eileen O'Reilly; | Clinical Trial In Progress | Antibody; Immune suppression; MDSC; Solid tumors |
| P420 | Broad immunogenicity from GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumor neoantigens | Roger Cohen, MD; Melissa L. Johnson, MD; Przemyslaw Twardowski, MD; Mark Stein, MD; Ulka N. Vaishampayan, MD; Maura L. Gillison, MD, PhD; Lisa K. McNeil, PhD; Louisa Dowal, PhD; James Foti, PhD; Parul Agnihotri, PhD; Daniel DeOliveira, PhD; Manish Jain, MS; Jessica Price; Richard Hernandez; Arthur P. DeCillis, MD; Narinderjeet Singh, MS, MBA; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; | Clinical Trial In Progress | Clinical trial; Immune adjuvant; Immune monitoring; Immune suppression; Neoantigens; Solid tumors; T cell; T cell lineages; Tumor antigens; Vaccine |
| P421 | Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors. | Ecaterina I. Dumbrava, MD; Gini F. Fleming, MD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Amita Patnaik, MD FRCP(C); Kyriakos P. Papadopoulos, MD; Adam ElNaggar, MD; John Hunter, PhD; Judy Olweny; Adeboye H. Adewoye, MD; Bartosz Chmielowski, MD, PhD; Dale Shepard, MD PhD; Manish R. Sharma, MD; Emerson Lim, MD; Daniel Vaena, MD; Drew Rasco, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P422 | Phase 1 study of COM701 monotherapy and in combination with nivolumab in patients with advanced solid tumors. | Ecaterina Dumbrava, MD; Gini Fleming, MD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Amita Patnaik, MD FRCP(C); Kyriakos P. Papadopoulos, MD; Adam ElNaggar, MD; John Hunter, PhD; Judy Olweny; Adewoye H. Adewoye, MD; Adeboye H. Adewoye, MD; Bartosz Chmielowski, MD, PhD; Dale Shepard, MD PhD; Manish R. Sharma, MD; Emerson Lim, MD; Daniel Vaena, MD; Drew Rasco, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P423 | SURPASS trial design: A phase 1 dose escalation trial to assess safety and efficacy of ADP-A2M4CD8 in HLA-A2+ patients with MAGE-A4+ tumors | Paula M. Fracasso, MD, PhD; David S. Hong, MD; Marcus Butler; Melissa L. Johnson, MD; Tanner Johanns; Francine Brophy; Rebecca Dryer-Minnerly, PhD; Trupti Trivedi, MS; Rafael Amado, MD; Paula M. Fracasso, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor antigens |
| P424 | Preliminary safety, efficacy and immunogenicity results from a phase 1/2a study (DIRECT-01) of cancer neoantigen DNA vaccine VB10.NEO in patients with locally advanced or metastatic solid tumors | Jürgen Krauss; Angela Krackhardt; Elke Jaeger; Anja Williams; Reza Rafiyan; LIsa Gerner; Monika Sekelja; Agnete B. Fredriksen, PhD; Karoline W. Schjetne; Mads Axelsen; Agnete B. Fredriksen, PhD; Hedda Wold, MSc; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Vaccine |
| P425 | Phase 1b study of GX-I7, a long-acting interleukin-7, evaluating the safety, pharmacokinetics and pharmacodynamics profiles in patients with advanced solid cancers | Minkyu Heo; Tae Won Kim, MD, PhD; | Clinical Trial In Progress | Biomarkers; Chemokine; Clinical study; Clinical trial; Cytokine; Immune adjuvant; Immune monitoring; Solid tumors; T cell |
| P426 | A first-in-human phase 1, multicenter trial of toll-like receptor (TLR) 7 agonist DSP-0509 as monotherapy and in combination with pembrolizumab in adult patients with advanced solid tumors | Shadia Jalal, MD; Jared Weiss, MD; Anthony J. Olszanski, MD, RPh; Jordan Berlin, MD; Makoto Origuchi; Zhonggai Li; Bella Ertik; Hongliang Cai; Daniel Clancy; Jose Iglesias; Vivek Subbiah, MD; Shadia Jalal, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR |
| P427 | A Phase 1 Study of IMC-001, Novel Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors | Bhumsuk Keam, MD, PhD; Tae Min Kim, MD, PhD; Do-Youn Oh, MD, PhD; Chan-Young Ock, MD, PhD; Won Ki Kang, MD, PhD; Yeon Hee Park, MD, PhD; Jeeyun Lee, MD, PhD; Ji Hye Lee, MD; Yun Jeong Song, MD; Young Suk Park, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Antibody; Clinical study; Clinical trial; Solid tumors; T cell |
| P428 | A phase 1 study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as stand-alone and in combination with BI 754091, a PD-1 inhibitor, in patients with advanced solid tumours | Nuria Kotecki, MD; Philippe Cassier; Jean-Pierre Delord, MD; Stéphane Champiat; Christiane Jungels; Armelle Vinceneux; Iphigenie Korakis; Richard Huhn; Nicolas Poirier; Dominique Costantini; Bérangère Vasseur; Aurélien Marabelle; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Targeted therapy |
| P429 | A phase 1/2a dose escalation and expansion study of HPN536, a mesothelin-targeting T cell engager, in patients with advanced cancers expressing mesothelin who have failed standard therapy | Erika P. Hamilton, MD; Richard Austin, PhD; Sue Hirabayashi; Che-Leung Law, PhD; Bryan Lemon, PhD; Holger Wesche, PhD; Debra Richardson, MD; | Clinical Trial In Progress | Antibody; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P430 | Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination with a PD-1 Inhibitor in Adult Subjects with Advanced or Metastatic Solid Tumors | David Luo; Raghad Abdul-Karim, MD; Arun Azad, MD; Joanna Bendell, MD; Hui Gan, MBBS PhD; Filip Janku, MD, PhD; Shiraj Sen, MD, PhD; Tira Tan, MBBS; Judy S. Wang, MD; Lisa Schechet; Lauren Baker, PhD; Joseph A. Leveque, MD; Tarek Meniawy, MBBS FRACP; | Clinical Trial In Progress | Clinical study; Clinical trial; Cytokine; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P431 | Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (TG-1501) in oncology patients | Lin Lin, PhD; James Hilbert; Leonid Gorelik; Jian-Ping Tang; James Oliviero; Joshua Apgar; Lore Gruenbaum, PhD; John Burke; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs) |
| P432 | A phase 1 dose-escalation study of safety, tolerability, and pharmacokinetics (PK) of ABBV-368 monotherapy and combination in patients (pts) with locally advanced or metastatic solid tumors | Christophe Le Tourneau; Wu-Chou Su, MD; Ki Y. Chung, MD; Patricia LoRusso, DO; Chia-Chi Lin, MD, PhD; Fabrice Barlesi, MD, PhD; Her-Shyong Shiah; Eric Angevin, MD; Alexander I. Spira, MD, PhD, FACP; Amita Patnaik, MD FRCP(C); John D. Powderly, II, MD, CPI; Dimitrios Colevas; Helen Chew, MD; Maulik Patel, PharmD, PhD; Stacie L. Lambert; Yan Li; Daniel Da Costa; Martha E. Blaney, PharmD; Michael A. McDevitt, MD, PhD; Philippe Cassier; | Clinical Trial In Progress | Antibody; Clinical trial; Regulatory T cell (Treg cell); Solid tumors |
| P433 | Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors | M R. Middleton, MD PhD; Joseph Sacco; Jaime Merchan; Amber Thomassen; Brendan D. Curti, MD; Ari M. VanderWalde, MD, MPH, MBioeth; Anna C. Olsson-Brown, MBChB (Hons), BSc (Hons); Francesca Aroldi; Nicos Fotiadis; Scott Baum; Howard L. Kaufman, MD, FACS; Kevin Harrington, MD; | Clinical Trial In Progress | Clinical study; Tumor microenvironment |
| P434 | A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers | Mehrdad Mobasher; Richard A. Miller; Brian Munneke; Deborah Strahs; Gabriel Luciano; Emily C. Piccione, PhD; Suresh Mahabhashyam; Jaime Merchan; John D. Powderly, II, MD, CPI; Lauren Harshman, MD; Minal Barve; Walter Stadler, MD; Patricia LoRusso, DO; Melissa Johnson; Abhishek Tripathi, MD; Sumanta K. Pal, MD; Ben Markman, MBBS FRACP; Jason J. Luke, MD, FACP; Thomas U. Marron, MD PhD; | Clinical Trial In Progress | Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; Solid tumors; Targeted therapy |
| P435 | A Window of Opportunity Trial Using Intratumoral Injection of Glatiramer as an Immune Modulator in Patients with Resectable Head and Neck and Cutaneous Squamous Cell Cancer | Ghulam Rehman Mohyuddin, MD; Joaquina C. Baranda, MD; Andres Bur; Lisa Shnayder; Kiran Kakarala; Terry Tsue; Prakash Neupane; Gregory Gan; Joshua Mammen; Daniel Aires; Sufi Thomas; Stephen Williamson; Nelli Lakis; Rashna Madan; Prabhakar Chalise; Scott Weir; Andrew Godwin; Greg Reed; Cory Berkland; | Clinical Trial In Progress | Biomarkers; Clinical trial; NK/NK T cell; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P436 | Phase 2 study of lenvatinib plus pembrolizumab in previously treated patients with solid tumors: LEAP-005 | Ravit Geva, MD; Seock-Ah Im; Zarnie Lwin; Susan Weil; Lei Xu; Anne Morosky; Kevin G. Norwood, MD; Hyun Cheol Chung, MD, PhD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P437 | Disease-related biomarkers are associated with extended progression free survival after treatment with NEO-PV-01 in combination with anti-PD1 in patients with metastatic cancers | Patrick A. Ott, MD, PhD; Ramaswamy Govindan, MD; Aung Naing, MD, FACP; Terence Friedlander, MD; Kim A. Margolin, MD; Jessica J. Lin, MD; Nina Bhardwaj, MD, PhD; Matthew Hellmann, MD; Mark Awad, MD PhD; Amy Wanamaker; Lisa D. Cleary; Michael Rooney; Julian Scherer, PhD; Meghan E. Bushway; Melissa Moles; Zakaria Khondker; Richard B. Gaynor, MD; Lakshmi Srinivasan, Ph.D; Andrew Chi; Joel Greshock; Siwen Hu-Lieskovan, MD, PhD; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Clinical study; Clinical trial; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| P438 | Phase 2 Multicenter Trial of ICOS agonist vopratelimab and a CTLA-4 inhibitor in PD-1/PD-L1 inhibitor experienced adult subjects with Non-small Cell Lung Cancer or Urothelial Cancer (EMERGE) | Russell Pachynski, MD; Ramaswamy Govindan, MD; Ellen Hooper, MD; Christopher Harvey, PhD; Amanda Hanson; Sean M. Lacey, MA Biostatistics; Rachel McComb; Courtney Hart; Haley Laken; Johan Baeck; Elizabeth G. Trehu, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Cytokine; Immune suppression; T cell; Targeted therapy; Tumor antigens |
| P439 | Phase 1 First in Human Study of Programmed Cell Death Receptor-1(PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects with Advanced Refractory Solid Tumor Malignancies | Kyriakos P. Papadopoulos, MD; Gerald S. Falchook, MD; Nehal Lakhani, MD, PhD; Gosia Riley; Jian Xu, PhD; Johan Baeck; Gilad S. Gordon; Elizabeth G. Trehu, MD; Judy S. Wang, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors; T cell |
| P440 | Phase 1/1b Multicenter Trial of TPST-1120, a Peroxisome Proliferator-Activated Receptor Alpha (PPARα) Antagonist as a Single Agent (SA) or in Combination in Subjects with Advanced Cancers | John D. Powderly, II, MD, CPI; Saurin Chokshi, MD; Johanna Bendell, MD; Leisha A. Emens, MD, PhD; Jason J. Luke, MD, FACP; Brian Francica; Chan C. Whiting, PhD; Thomas W. Dubensky, Jr., PhD; Ginna G. Laport, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Metabolism; Solid tumors; Tumor microenvironment |
| P441 | ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | John D. Powderly, II, MD, CPI; Bradley C. Carthon, MD, PhD; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; Stephen V. Liu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Ulka N. Vaishampayan, MD; | Clinical Trial In Progress | Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors |
| P442 | A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors | Amy AP. Prawira, MD; Jermaine Coward; Hui Gan, MBBS PhD; James Kuo; Michael Millward; Gary Richardson; Wei Deng; Siddhartha Mitra; Maike Schmidt; Hong Xiang, PhD; Lisa Horvath; Amy AP. Prawira, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell |
| P443 | Expansion cohorts of non-small cell lung cancer (NSCLC) and castration resistant prostate cancer (CRPC) in COSMIC-021, a phase 1b study of cabozantinib plus atezolizumab | Nick Salgia, PhD; Sumanta K. Pal, MD; Santiago Ponce Aix, MD; Yohan Loriot; Robert Dreicer; Ulka N. Vaishampayan, MD; Toni K. Choueiri; Patrick Schöffski; Giri Ramsingh; Amy Liu; Farah L. Lim; Joel Neal, MD, PhD; Neeraj Agarwal, MD; | Clinical Trial In Progress | Clinical trial; Solid tumors |
| P444 | The Quest for Highly Potent Human Papillomavirus-Specific T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies | Pei Yun Teo, PhD; Sandhya Sharma, BSc.; Alex Salyer; Dimitrios L. Wagner; Benjamin Shin; Sachin Thakar; Li-Chun Huang; Shian Jiun Shih; Carlos Ramos; Cliona M. Rooney, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P445 | Preliminary results of a Phase 1 trial with a personalized neoantigen vaccine (ADXS-NEO) in advanced and refractory cancer patients | Frank Y. Tsai, MD; Jonathan W. Goldman, MD; Marc R. Matrana; Sumitra Sheeri; John Heyburn; Megan Parsi; Andres A. Gutierrez, MD PhD; Joel R. Hecht; Joel R. Hecht; | Clinical Trial In Progress | Antigen presenting cells; Biomarkers; Clinical study; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P446 | A Novel Regulatory T Cell-Targeted Immunotherapy by targeting their Crucial Signal by HSP90 Inhibitors | Ayaka Tsuge, MD; Yosuke Togashi, MD, PhD; Kohei Shitara, MD; Hiroyoshi Nishikawa, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical trial; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment |
| P447 | ALKS 4230, an engineered IL-2 fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors: ARTISTRY-1 trial | Ulka N. Vaishampayan, MD; Jameel Muzaffar, MD; Vamsidhar Velcheti, MD, FACP; Christopher J. Hoimes, DO; Lucy Gilbert, MD; David F. McDermott, MD; Anna Spreafico, MD PhD; Quincy Chu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Harald Mackenzie, MB; Lei Sun, PhD; Emily L. Putiri, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Marc S. Ernstoff, MD; | Clinical Trial In Progress | Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors |
| P448 | Phase I Study of Veliparib and Nivolumab in Adults with Refractory Advanced Solid Tumor and Lymphoma | Young Kwang Chae, MD; Pedro Viveiros, MD; Sheetal Kircher; Valerie Nelson; Aparna Kalyan; Devalingam Mahalingam; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant |
| P449 | Pharmacodynamic biomarker characterization of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy | Hong Wan, PhD; Laura Q. Chow, MD; Justin F. Gainor, MD; Nehal Lakhani, MD, PhD; Hyun C. Chung, MD, PhD; Keun-Wook Lee, MD; Jeeyun Lee, MD, PhD; Patricia LoRusso, DO; Yung-Jue Bang, MD PhD; Stephen Hodi; Wells Messersmith, MD; Philip Fanning, PhD; Pierre Squifflet; Feng Jin; Tracy Kuo; Sangeetha Bollini; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune suppression; Monocyte/Macrophage; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P450 | A Phase I/IIa, Open-label, Dose-Escalation and expansion study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients with Advanced Solid Tumors | Jin Li; Ye Guo; Wei Peng; Junli Xue; Wei Zhao; Xiaoxiao Ge; Liqiong Xue; Wenbo Tang; Li Zhou; Min Zhang; Bingshi Guo; Liping Wang, MD; Jiyuan Guo; Feifei Cui, PhD; Haiyun Suo; | Clinical Trial In Progress | Clinical trial; Cytokine; Solid tumors; T cell |
| P451 | First-in-human study of CD40 agonist MEDI5083 in advanced solid tumors with durvalumab administered sequentially or concurrently | Ben Tran, MBBS FRACP; Mark Voskoboynik; Johanna Bendell, MD; Martin Gutierrez, MD; Charlotte R. Lemech, MBBS BSc(med) MD(res); Daphne Day; Sophia Frentzas; Ignacio Garrido-Laguna; Chris DelNagro; Fujun Wang; Charles Ferte, MD, PhD; Mayukh Das; Benedito A. Carneiro, MD; Ben Tran, MBBS FRACP; | Clinical Trial In Progress | Antibody; Antigen presenting cells; Checkpoint blockade; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P452 | SPEARHEAD-1 trial design: A phase 2, single arm, open-label clinical trial of ADP-A2M4 SPEAR T-cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma | Dejka Araujo, MD; Jean-Yves Blay; Sandra Strauss; Claudia Valverde; Erin Van Winkle; Malini Iyengar, PhD; Rafael Amado, MD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P453 | Autologous T cells with NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-A*02+ previously-treated and -untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design | Sandra P. D'Angelo, MD; Jean-Yves Blay; Warren Chow; George D. Demetri; Fiona Thistlethwaite, MD, PhD; Michael Wagner; David Loeb; Steven Attia; Albiruni R. Razak; John Haanen, MD PhD; Aisha N. Hasan, MBBS MD; Julia Billiard; Laura Pearce; Yuehui Wu; Ran Ji; Laura Johnson; Chandra Srinath; Aiman Shalabi; Sandra Strauss; Katherine Thornton; Crystal L. Mackall, MD; William Tap; Brian Van Tine, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; CAR T cells; Clinical trial; T cell; Targeted therapy |
| P454 | Induction of serum CXCL10 by tebentafusp, a gp100-CD3 bispecific fusion protein, was associated with survival in uveal melanoma in a Phase I/II Study | Marcus O. Butler, MD; Brandon W. Higgs; Cheryl McAlpine, MSN; Joseph Sacco; Jessica C. Hassel, MD; Shaad E. Abedin, MD, FACP; Koustubh Ranade, PhD; Richard Carvajal, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Clinical trial; Solid tumors; Tumor antigens |
| P455 | A randomized phase 2 study of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery vs surgery for resectable stage IIIB-IVM1a melanoma: 2-year primary analysis of recurrence-free survival (RFS) | Reinhard Dummer, MD; David E. Gyorki; John Hyngstrom, MD; Adam C. Berger, FACS, MD; Robert M. Conry, MD; Lev Demidov; Anjali Sharma; Sheryl A. Treichel; Kevin Gorski; Abraham Anderson, PhD; Mark Faries; Merrick Ross, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Clinical trial; Immune contexture; Inflammation; Solid tumors; Surgery |
| P456 | KEYNOTE-630: phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma | Jessica L. Geiger; Gregory A. Daniels, MD, PhD; Ezra Cohen, MD; Joy Yang Ge; Burak Gumuscu, MD PhD; Ramona F. Swaby, MD; Anne Lynn S. Chang; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune adjuvant; Solid tumors |
| P457 | Randomized Phase II Neoadjuvant Study: PD-1 Inhibitor TSR-042 vs. Combination PD-1 Inhibitor TSR-042 and Tim-3 Inhibitor TSR-022 in Borderline Resectable Stage III or Oligometastatic Stage IV Melanoma | Zahra Kelly, DO; Yana G. Najjar, MD; Hassane M. Zarour, MD; John M. Kirkwood, MD; Suthee Rapisuwon, MD; Hong Wang; Marc S. Ernstoff, MD; Joseph J. Drabick, MD, FACP, FIDSA; Diwakar Davar, MD; Mohan Bala; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell |
| P458 | A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma | Julia Katharina Schwarze, MD, MSc; Gil Awada; Louise Cras; Inès Dufait; Ramses Forsyth; Ivan Van Riet; Bart Neyns; | Clinical Trial In Progress | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; Tumor microenvironment; Vaccine |
| P459 | New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor | Chengfei Pu; Lei Xiao, PhD; | Clinical Trial In Progress | CAR T cells; Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy; Tumor antigens |
| P460 | A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer | Hoyoung M. Maeng, MD; Lauren V. Wood, MD; Seth Steinberg; David F. Stroncek, MD; Masaki Terabe, PhD; Jay A. Berzofsky, MD, PhD; | Clinical Trial In Progress | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine |
| P461 | Phase 1b study of INCMGA00012, a programmed cell death-1 (PD-1) inhibitor, in combination with chemotherapy in patients with advanced solid tumors (POD1UM-105) | David Planchard, MD, PhD; Jill Bowman; Nawel Bourayou, MD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors |
| P462 | ImmTAC®-chemotherapy combination: A preclinical evaluation shows potential benefits | Adel Benlahrech, BSc PhD; Filipa Bravo-Lopes; Nora Rippaus; Kristina Petrovic; Francesca Amicarella; Adam Taylor; Laure Humbert; Rupert Kenefeck; Adel Benlahrech, BSc PhD; | Combination Immunotherapies | Chemotherapy; T cell; Targeted therapy |
| P478 | SEMA4D antibody blockade overcomes mechanisms of immune suppression and combination immunotherapy including TGFβ blockade promotes efficient tumor regression | Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Crystal Mallow, BS; Holm Bussler, PhD; Sebold Torno, BS; Desa Rae Pastore; Alan Howell, MS; Luis I. Ruffolo, MD; Nicholas Ullman; Brian A. Belt, JD; Joe Bucukovski; Christine Reilly, BS; Benjamin Dale; Ernest S. Smith, PhD; David C. Linehan, MD; Maurice Zauderer, PhD; Elizabeth E. Evans, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Clinical trial; Immune suppression; Myeloid cells; MDSC; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P481 | Obesity impairs immunotherapeutic efficacy in pre-clinical breast cancer | Justin T. Gibson, BS; Rachael M. Orlandella, BS; William J. Turbitt; Robert E. Sorge, PhD; Lyse A. Norian, PhD; | Combination Immunotherapies | Immune suppression; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P482 | STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies | Laura H. Glickman, PhD; Christopher Rae, PhD; Alexandre Iannello, PhD; Anastasia M. Makarova, PhD; Haixing Kehoe, MS; John Faulhaber; Bill Hanson; Christopher Thanos, PhD; | Combination Immunotherapies | Chemokine; Cytokine; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P491 | Preclinical Development of a Novel TNFRSF25 Agonist Antibody, PTX-35, for Cancer Immunotherapy Combinations | Matthew M. Seavey, PhD; Jayalakshmi Miriyala, MS; Jason Rose, MS; Vikas Tahiliani, PhD; Patrick Dillon, PhD; Elena Gorovits, PhD; Jeff Hutchins, PhD; Rahul R. Jasuja, PhD; | Combination Immunotherapies | Antibody; Immune adjuvant; Inflammation; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P509 | Myeloid Cell-Selective STAT3 Inhibition Sensitizes Head and Neck Cancers to Radiation Therapy and Stimulates T-cell-Dependent Tumor Regression | Marcin Kortylewski, PhD; Dayson F. Moreira, PhD; Marcin Kortylewski, PhD; Sagus Sampath; Haejung Won; Chongkai Wang; Peter P. Lee, MD; Ellie Maghami; Erminia Massarelli, MD, PhD, MS; William C. Spanos, MD; Seok White; | Combination Immunotherapies | Clinical study; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Radiotherapy; Solid tumors; TLR; Tumor microenvironment |
| P520 | Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/ metastatic renal cell carcinoma | Yufei Wang; Yichen Zhong, PhD; Shahrul Mt-Isa; Rodolfo Perini, MD; Oluwakayode Adejoro, MD, MPH; Oluwakayode Adejoro, MD, MPH; Oluwakayode Adejoro, MD, MPH; | Combination Immunotherapies | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| P522 | Preclinical development of M4112, an IDO1/TDO2 dual selective and orally bioavailable small molecule inhibitor, and combination with avelumab, for treatment of solid tumors | Jieqing Chen, MD; Chia Lin Chu, PhD; Feng Jiang, PhD; Chunxiao Xu, PhD; Yanping Zhang; Sireesha Yalavarthi; Molly Coop; Hong Wang; Yanyan Wang; Bettina Hanschke; Anindya Siddharta; Sen Zhang; Amit Deshpande; Bartholomew Naughton, PhD; Filippos Porichis; Tai-An Lin, PhD; Joern-Peter Halle; Tilo Senger; Brian Sherer; Jacques Moisan; | Combination Immunotherapies | Checkpoint blockade; Coinhibition; Immune suppression; Metabolism; Solid tumors; Tumor evasion; Tumor microenvironment |
| P539 | Management of Melanoma: Education Improving Clinical Decisions of Oncologists | Kinjal Parikh, PharmD; Haleh Kadkhoda, MS; Jeffrey S. Weber, MD, PhD; Charlotte Warren; Ann Carothers, MEd; | Education and Treatment Management | Checkpoint blockade; Solid tumors |
| P566 | Does Loss of BAP-1 influences the activation of Non-canonical NFκB pathway in uveal melanoma with inflammation? | Mithalesh Kr. Singh; Lata Singh, PhD; Seema Kashyap; Neelam Pushker, MD; Seema Sen, MD; Rachna K. Meel, M.D; | Immune Cell Biology | Biomarkers; Clinical study; Cytokine; Gene expression; Inflammation; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P569 | Immune tumor microenvironment dictates clinical outcome of oropharyngeal carcinoma upon standard therapy. | Marij J. Schoenmaekers-Welters, PhD; Saskia Santegoets; Chantal Duurland; Vanessa J. van Ham; Ilina Ehsan; Sjoerd H. van der Burg, PhD; | Immune Cell Biology | Biomarkers; Cytokine; Immune contexture; Immune suppression; Inflammation; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P579 | Predictive and prognostic relevance of CD8+ tumor-infiltrating lymphocyte density combined with PD-L1 expression in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy | Changhoon Song, MD; Yoonjin Kwak; Hye Seung Lee; Sung-Bum Kang; Jae-Sung Kim; | Immune Cell Biology | Biomarkers; Chemotherapy; Clinical study; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P586 | Comprehensive immune profiling of clinical samples from subjects with advanced recurrent epithelial ovarian cancer treated with a novel T cell activating therapy, DPX-Survivac | Brennan S. Dirk, PhD; Heather Torrey, PhD; Yogesh Bramhecha, PhD; Olga Hrytsenko, PhD; Stéphan Fiset; Marianne Stanford, PhD; | Immune Cell Biology | Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P592 | TGFβR1 antagonism improves radiation efficacy by enhancing CXCR3 dependent tumor recruitment of CD8+ T cells | Andrew J. Gunderson, PhD; Tomoko Yamazaki, PhD; Kayla McCarty, BS; Nathaniel Fox; Michaela Phillips, BA; Alejandro Alice, PhD; Tiffany Blair; Mary McCormick, RN; Andrea Burt, RN; Iliana L. Gonzalez, BS; Mark Whiteford, MD; David O'Brien; Rehan Ahmad; Maria X. Kiely, MD; Amanda V. Hayman, MD, MPH; Rui Li, MD, PhD; Todd Crocenzi, MD; Michael J. Gough, PhD; Marka R. Crittenden, MD, PhD; Kristina H. Young, MD, PhD; | Immune Cell Biology | Chemokine; Chemotherapy; Clinical trial; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P605 | Severity of Cytokine Release Syndrome as a Predictor of Infections after T-cell replete Haploidentical Hematopoietic Cell Transplantation (haploHCT) | Muhammad Bilal Abid, MD, MRCP (UK); Parameswaran Hari, MBBS, MD, MRCP; Aniko Szabo; Mehdi Hamadani; Mary Beth Graham; Saurabh Chhabra; | Immune Cell Biology | Chemotherapy; Clinical study; Cytokine; Immune toxicity; Inflammation; Leukemia/Lymphoma; T cell |
| P606 | ICOSL on human dendritic cells is critical for priming T cell responses | Deena M. Maurer, MS; Juraji Adamik, PhD; Patricia M. Santos, PhD; Jian Shi, MD; Jennifer L. Taylor, PhD; Michael R. Shurin, phD; John M. Kirkwood, MD; Walter J. Storkus, PhD; Lisa H. Butterfield, PhD; | Immune Cell Biology | Antigen presenting cells; Clinical study; Costimulation; Dendritic cell; T cell; Vaccine |
| P697 | Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers | Francesca Zammarchi, PhD; Simon Chivers; Patrick H. van Berkel, Ph.D; Francesca Zammarchi, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Checkpoint blockade; Chemotherapy; Clinical trial; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P708 | Real world evidence of patient clinical profiles with advanced solid tumor malignancies receiving immune checkpoint inhibitors to investigate potential predictors for immune-related adverse events. | Stephanie Berg, DO; Joseph I. Clark, MD; Jose Guevara; Elizabeth Elliott, DO; Stephanie Berg, DO; Stephanie Berg, DO; Michael Wesolowski; Blaine Knox, MD; Daniel Linden, DO; Courtney Wagner, MD; | Immunotherapy Toxicities | Biomarkers; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| P714 | Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition | Meghali Goswami, MPhil; Gege Gui; Katherine E. Lindblad; Jaydira Del Rivero, MD; Jennifer Marte, BS MD; Pradeep K. Dagur, PhD; Christin B. Destefano, MD; Julie Thompson, RN; Bogdan Popescu, MD; Laura Dillon, PhD; Cheryl D. Johnson; Steven J. Soldin, PhD; Catherine Lai, MD, MPH; James L. Gulley, MD, PhD, FACP; Christopher S. Hourigan, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune toxicity; Leukemia/Lymphoma; T cell |
| P715 | Strategies to mitigate immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer | Célia Jacoberger-Foissac, PhD; Stephen J. Blake; Célia Jacoberger-Foissac, PhD; Jing Liu; Stacey Allen; Juming Yan; Heidi Harjunpaa; Mark J. Smyth; Michele W. Teng, PhD; | Immunotherapy Toxicities | Antibody; Autoimmunity; Cytokine; Immune suppression; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors |
| P725 | Clinical features of immune checkpoint inhibitor-related adrenal insufficiency: a retrospective analysis | Qinwen Zhou, MD; Sandip P. Patel, MD; Qinwen Zhou, MD; Vala Hamidi; Qinwen Zhou, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors |
| P735 | Accelerating biomarker discovery using AI powered multi- omics approaches | Madhuri Gadekar; Mohan Uttarwar; Shruti Desai; Sanjay Khare; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Clinical trial; Immune monitoring; Immunoscore |
| P737 | Model-Based Meta-Analysis of the Exposure-Response and Clinical Efficacy across Approved Anti-PD(L)1 Agents | Apurvasena Parikh, PhD; Sreeneeranj Kasichayanula, PHD; Rajeev Menon; Megan Gibbs; Sven Mensing; Benjamin Engelhardt; | Machine Learning, Artificial Intelligence, and Computational Modeling | Antibody; Checkpoint blockade; Solid tumors |
| P738 | Artificial intelligence-based tumor purity assessment of digitized histology samples in multiple tumor types from clinical trials of nivolumab | George Lee, PhD; Sujaya Srinivasan; Natallia Kalinava; Ariella Sasson; Vipul Baxi, MS; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Clinical trial; Tumor stroma |
| P746 | Global metabolomics of advanced gastric cancer patients identifies signatures associated with response and clinical benefit from nivolumab | Carrie B. Brachmann, PhD; Daniel Cooper; Kari Wong; Ethan Grant; Daniel V. Catenacci, MD; David Cunningham; Jean-Philippe Metges; Eric Van Cutsem, MD, PhD; Zev Wainberg, MD; Dung Thai; Pankaj Bhargava; Emon Elboudwarej; Ondrej Podlaha; Wadud Khan; Jennifer A. Wargo, MD, MMSc; Manish Shah, MD; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Metabolism; Microbiome; Solid tumors |
| P753 | Trial in progress: A phase I study of live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours | John D. Weinberg, MD; Jonathan Krell, PhD, MRCP, MBChB, BSc; | Microbiome and other environmental factors | Clinical study; Clinical trial; Cytokine; Microbiome; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P768 | Antagonism of Signaling through the Vasoactive Intestinal Peptide Receptor as a Novel Immunotherapy in Preclinical Models of Melanoma. | Rohan K. Dhamsania, BS; Sruthi Ravindranathan, PhD; Shuhua Wang, MD; Rebecca A. Pankove, MS; David Francis; Susan N. Thomas, PhD, BS; Brian Pollack; Edmund K. Waller, MD, PhD, FACP; | Novel Single-Agent Immunotherapies | Adoptive immunotherapy; Checkpoint blockade; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P783 | DuoBody®-CD3x5T4 shows potent preclinical anti-tumor activity in vitro and in vivo in a range of cancer indications | Kristel Kemper, PhD; Ellis Gielen; Laura Smits-de Vries; Sandra Verploegen; Mischa Houtkamp; Saskia Burm; Edward van den Brink; Rik Rademaker; Dennis Verzijl; Patrick Engelberts; Bart E.C.G. de Goeij; David Satijn; A. Kate Sasser; Esther Breij, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P795 | Anti-MUC1 monoclonal antibodies derived from the first non-viral prophylactic cancer vaccine clinical trial can target cancer cells and facilitate their immune-mediated elimination | Michelle L. McKeague, PhD; Jason Lohmueller, PhD; Eric Ricci; William Lu; Olivera J. Finn, PhD; | Novel Single-Agent Immunotherapies | Antibody; NK/NK T cell; Vaccine |
| P805 | SRF388, a first-in-class, fully human monoclonal antibody targeting IL 27, blocks the immunoregulatory effects of IL-27 in immune cells and demonstrates preclinical in vivo antitumor activity | Matthew P. Rausch, PhD; Jing Hua; Devapregasan Moodley; Kerry F. White; Katherine H. Walsh; Christine E. Miller; Jamie Strand; Pamela Holland, PhD; Vito J. Palombella, PhD; Jonathan A. Hill, PhD; | Novel Single-Agent Immunotherapies | Antibody; Cytokine; Immune suppression; T cell |
| P809 | Preclinical Development of a Novel, Allogeneic, OX40L-Secreting, Therapeutic Cancer Vaccine for use in Combination with a gp96-Secreting Vaccine for Solid Tumors | Matthew M. Seavey, PhD; Jason Rose, MS; Patrick Dillon, PhD; Jayalakshmi Miriyala, MS; Vikas Tahiliani, PhD; Jeff Hutchins, PhD; | Novel Single-Agent Immunotherapies | Immune adjuvant; Tumor antigens; Vaccine |
| P826 | Preliminary results of a Phase 2 study of INCMGA00012 in patients with squamous carcinoma of the anal canal (SCAC) who have progressed following platinum-based chemotherapy (NCT03597295) | Sheela Rao; Jaume Capdevila; Duncan Gilbert; Stefano Kim; Laetitia Dahan; Talal Kayyal; Marwan Fakih, MD; Anne Demols; Mark Cornfeld, MD, MPH; Chuan Tian, PhD; Melissa Catlett; Jean-Philippe Spano; | Other | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P827 | Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers | Rachel E. Sanborn, MD; Nashat Y. Gabrail, MD; Mark O'Hara, MD; Nina Bhardwaj, MD, PhD; Michael S. Gordon, MD; Ralph J. Hauke, MD; Rodolfo E. Bordoni, MD; Danny Khalil, MD PhD; Tracey Rawls; Laura Vitale, BS; Richard Gedrich; Thomas Hawthorne; Tibor Keler, PhD; Eirc Forsberg, BS; Lawrence Thomas, PhD; Michael Yellin, MD; | Other | Antibody; Antigen presenting cells; Clinical study; Costimulation; Dendritic cell; Immune monitoring |
| P828 | Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR–anti-CD3 directed against gp100, in patients with advanced melanoma | Alexander N. Shoushtari, MD; Mark R. Middleton; Neil M. Stevens; Thomas J. Evans; Jeffrey R. Infante; Mario Sznol, MD; Alan Anthoney; Avinash Gupta; Victoria Woodcock; Tina Wiseman; Cheryl McAlpine, MSN; Chris Cohen; Omid Hamid, MD; | Other | Biomarkers; Chemokine; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell; Targeted therapy |
| P831 | Inclusion of people living with HIV in anti-PD(L)1 clinical trials: Results of an NCI-driven initiative to broaden eligibility in clinical trial development | Joshua E. Reuss, MD; Diana Stern, MD; Ramya Ramaswami; Kathryn Lurain, MD; Helen Chen, MD; Howard Streicher, MD; Ravie Kem, RPh, Pharm D, MPH; Richard F. Little, MD; Elad Sharon, MD, MPH; | Regulatory, Financial, and Access Considerations | Checkpoint blockade; Clinical trial |
| P832 | Systematic literature review (SLR) of intravenously (IV) administered oncology therapies for which a subcutaneous (SC) formulation has also been developed | Brad Schenkel, MSc; Elise Wu; Ali McBride; Marília Hernani; Robin Wyn; Klaudia Kornalska; | Regulatory, Financial, and Access Considerations | Clinical study; Targeted therapy |
| P841 | NCG/CRL as a novel (Charles River) humanized mouse model for pre-clinical oncology studies: immunophenotypic characterization and performance monitoring | Jenny Rowe, PhD; Christoph CE. Eberle, PhD; Jenny Rowe, PhD; Robert Mihalek, PhD; Stephen Festin; | Tumor and Stromal Cell Biology | Checkpoint blockade; Immune monitoring; Leukemia/Lymphoma; Myeloid cells; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P849 | Melanoma-associated vitiligo skin maintains resident memory CD8 T cells with specific TCR profiles contributing to long-term tumor protection | Jichang Han, PhD candidate; Aleksey Molodtsov; Yanding Zhao; Keisuke Shirai, MD; Mary Jo Turk; Christina V. Angeles, MD; | Immune Cell Biology | Autoimmunity; Bioinformatics; Checkpoint blockade; Clinical study; Gene expression; Immune toxicity; Solid tumors; T cell |
| P856 | AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: Results of a Phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients | Timothy Yap, MD PhD , Daniel Araujo, Debra Wood, MD, Jean-François Denis, PhD, Tina Gruosso, PhD, Gilles Tremblay, PhD, Maureen O'Connor-McCourt, Ria Ghosh, Sandra Sinclair, Paul Nadler, MD, Lilian Siu, MD, Nehal Lakhani, MD, PhD | Clinical Trial Completed | Biomarkers; Clinical study; Clinical trial; Solid tumors; Tumor microenvironment; Tumor stroma |
| P858 | An Open-Label, Multi-center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with Cemiplimab in Subjects with Newly-Diagnosed Glioblastoma (GBM) | Jeffrey Skolnik, MD , David Reardon, MD, Steven Brem, MD, Arati Desai, Stephen Bagley, Sylvia Kurz, Macarena de la Fuente, Seema Nagpal, Mary Welch, Brian Sacchetta, Sarah Bartra, Amy-Lee Bredlau, Israel Lowy, MD, PhD, Kimberly Kraynyak, BS PhD, Matthew Morrow, Trevor McMullan, Jean Boyer, PhD | Clinical Trial In Progress | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Clinical trial; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P859 | Association of immunopharmacodynamic responses of Imprime PGG plus Pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy | Nadine Ottoson, BS, Nandita Bose, PhD , Anissa Chan, PhD, Xiaohong Qiu, BS, Ben Harrison, MS, Richard Walsh, BS, Paulette Mattson, BFA, Michele Gargano, MS, Joanna Cox, MD, Michael Chisamore, PhD, Mark Uhlik, PhD, Jeremy Graff, PhD | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Monocyte/Macrophage; Myeloid cells; Solid tumors |
| P860 | Results from a combination of OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a Phase 1 dose expansion cohort | Alberto Chiappori, MD , John Thompson, Fredericus Eskens, Jean-Philippe Spano, Toshihiko Doi, MD, PhD, Omid Hamid, MD, Adi Diab, MD, Naiyer Rizvi, MD, Siwen Hu-Lieskovan, MD, PhD, Willeke Ros, MSc0, Jacob Thomas, Alison Forgie, Wenjing Yang, Ken Liao, Ray Li, Farhad Kazazi, Jeffrey Chou, MD PhD, Anthony El khoueiry | Clinical Trial In Progress | Antibody; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P862 | Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with Imprime PGG and Pembrolizumab | Anissa Chan, PhD, Nandita Bose, PhD , Nandita Bose, PhD, Nadine Ottoson, BS, Xiaohong Qiu, BS, Ben Harrison, MS, Richard Walsh, BS, Paulette Mattson, BFA, Michele Gargano, MS, Joanna Cox, MD, Michael Chisamore, PhD, Mark Uhlik, PhD, Jeremy Graff, PhD | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Immune suppression; Myeloid cells; T cell |
| P863 | KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma | Michele Maio, MD, PhD , Matteo Carlino, MBBS, PhD, BMedSC, F, Anthony Joshua, Elaine McWhirter, Antoni Ribas, MD, PhD, Paolo Ascierto, Wilson Miller Jr., Marcus Butler, MD, Pier Ferrucci, Robert Zielinski, Michele Del Vecchio0, Eduard Gasal, Razi Ghori, PhD, Scott Diede, MD PhD, Elizabeth Croydon, Omid Hamid, MD | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P864 | Combination of fecal microbiota transplantation from healthy donors with anti-PD1 immunotherapy in treatment-naïve advanced or metastatic melanoma patients | Saman Maleki, PhD , John Lenehan, Jeremy Burton, Michael Silverman, Seema Nair Parvathy, Mikal El-Hajjar, Mithunah Krishnamoorthy | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Microbiome; T cell |
| P865 | Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies - independent review committee data update | Amod Sarnaik, MD, Nikhil Khushalani, MD, Jason Chesney, MD, Harriet Kluger, MD, Brendan Curti, MD, Karl Lewis, MD, Theresa Medina, MD, Sajeve Thomas, Anna Pavlick, MD, MBA, Eric Whitman, MD, FACS, Salvador Algarra, Pippa Corrie, PhD, BMBCh, FRCP0, Omid Hamid, MD, Jose Lutzky, MD, FACP, Judit Olah, MD, PhD, Jeffrey Weber, MD, PhD, James Larkin, MD, Wen Shi, Kelly DiTrapani, RN, BSN, Harry Qin, PhD, Mariam Mirgoli, Renee Wu, Toshimi Takamura, BS, Maria Fardis, PhD, MBA, John Kirkwood, MD | Clinical Trial In Progress | Adoptive immunotherapy; Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
© 2019 Society for Immunotherapy of Cancer (SITC). All rights reserved. SITC Meeting Code of Conduct.
